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The epidemic of maternal obesity is increasing worldwide. Simple, effective and acceptable 
interventions are needed to combat obesity and improve pregnancy outcomes in women with 
metabolic risk factors such as dyslipidaemia and obesity. Dietary and lifestyle interventions 
reduce gestational weight gain, however, their effect on maternal and fetal outcomes is not 
clearly known. I conducted a large pragmatic randomised trial to evaluate the effectiveness of 
a Mediterranean-based dietary intervention to reduce the risk of adverse maternal and fetal 
outcomes in pregnant women with metabolic risk factors (The ESTEEM trial). The 
intervention significantly reduced gestational diabetes and gestational weight gain by an 
average of 1.2 Kg with some protective effect on fetal outcomes. I analysed the 
methodological challenges encountered in the trial and discussed applied solutions.  
 
I conducted a systematic review on the commonly used dietary assessment tools in trials 
involving pregnant women to assess their characteristics, validity, and applicability. Self-
reporting dietary tools were the most commonly used to assess dietary intake in pregnancy 
such as food frequency questionnaires. Only 8% of studies validated the chosen tools and 
applied a defined adherence criterion.  I applied the findings of this review to develop and 
validate a custom designed food frequency questionnaire, and a short 12 items questionnaire, 
to assess the participants’ adherence in the ESTEEM study. I assessed the dietary intake in a 
randomised cohort from the ESTEEM study and compared the questionnaires’ accuracy to 24 
hour dietary recalls as the reference method. Both the FFQ and the short questionnaire 
performed well for assessing the adherence to and the intake of key foods in the 
Mediterranean diet.  
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I systematically reviewed available online information sources on the risks and management 
of obesity in pregnancy in the English language. I assessed 53 websites for their information 
credibility, accuracy, readability, content and technological quality. Overall I found that non-
governmental funded websites that are obesity-specific and targeting healthcare users 
presented better overall information quality.  
 
Objectives 
1. To evaluate the effect of a Mediterranean-based dietary intervention on maternal and 
fetal outcomes in pregnant women with metabolic risk factors (ESTEEM trial). 
2. To explore potential methodological challenges and solutions for randomised trials 
evaluating dietary interventions in pregnancy.  
3. To assess the quality of available tools to evaluate dietary intake in pregnancy. 
4. To evaluate the quality of available online information on the management and risks 
of obesity in pregnancy. 
5. To develop and validate accurate dietary assessment tools to measure participants’ 
adherence to a Mediterranean-based dietary intervention in pregnancy. 
 
Methods 
The methods used by me in my thesis to address the above objectives are as follows: 
 Multicentre randomised trial (objective 1, 2) 
 Systematic review of observational studies (3,4) 
 Primary study on quality of website (4)  





The ESTEEM study involved 1252 randomised women with metabolic risk factors. There 
was some protective effect of the dietary intervention on reducing the primary maternal 
outcome (OR 0.76, 95% CI 0.56-1.03, p=0.07) with more visible effect against GDM (OR 
0.65, 95% CI 0.47-0.91, p=0.01) than pre-eclampsia (OR 1.43, 95% CI 0.84-2.43, p=0.19). 
The protective effect of the intervention on the primary composite fetal outcome was more 
evident (OR 0.59, 95% CI 0.32-1.07, p=0.07) when accommodating for adherence with the 
intervention. The dietary intervention significantly reduced gestational weight gain (OR -
1.24, 95% CI -2.27-0.21, p=0.018). Delivering the intervention resulted in a significant 
change of dietary intake towards a Mediterranean-based diet with participants in the 
intervention group consuming more key foods items including extra virgin olive oil 
(p=<0.001), nuts (p=<0.001), pulses (p=0.047), fish (p=<0.001), and white meat (p=<0.001). 
They also consumed less red meat (p=<0.001), and butter margarine (p=<0.001).  
  
There were five key challenges encountered in ESTEEM, recruiting participants, delivering 
the intervention, engaging the clinical staff at recruiting centers, assessing the participants’ 
adherence and finally deciding on the relevant outcome measures. We increased the number 
of recruiting centres and the recruitment period. We engaged clinical staff through a number 
of tailored training and education sessions. We designed the intervention sessions to involve 
partners and the whole family where possible to improve adherence. We developed and 
validated a short user-friendly dietary questionnaire to assess the adherence in the ESTEEM 





Out of 58 dietary trials in pregnancy, only 39 used dietary assessment tools in their design. 
The most commonly used assessment tool was a multiple-days food diary (23/39, 59%) and a 
food frequency questionnaire (FFQ) (12/39, 31%). Only three studies validated their 
assessment tools and three used pre-defined criteria to assess participants’ adherence to the 
intervention. The rationale for using a particular tool was poorly reported with no apparent 
association with study characteristics.  
 
We assessed 53 websites for their information and technological quality. Obesity-specific 
websites provided lower credibility compared to general health websites (p=0.008). Websites 
targeting health users were easier to read (p=0.001). Non-governmental funded websites 
demonstrated higher content quality (p=0.005). Websites that are obesity focused, targeting 
health users and funded by non-governmental bodies demonstrated higher composite quality 
scores (p=0.048).   
 
The agreement between the FFQ and the 24h recalls was good for key foods in the 
Mediterranean diet such as meat (ICC 0.56), and fish (ICC 0.52). The agreement for olive oil 
and nuts intake was poor with moderate quintile cross-classification agreement. There was a 
good agreement in 8 out of 12 questions in the ESTEEM Q with their matched values from 
the FFQ. The total index score did not correlate well between the ESTEEM Q and the FFQ 





A Mediterranean-based dietary intervention is helpful to reduce gestational diabetes and 
gestational weight gain in a high risk pregnant population. The solutions to methodological 
challenges encountered in ESTEEM can help future trials on diet in pregnancy to boost 
adherence, engage clinical staff and define outcomes. The use of self-reporting dietary 
assessment tools is popular in dietary trials but limited in validity and applicability. The food 
frequency and short questionnaires developed for the ESTEEM study are useful tools to 
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1.1 Maternal obesity and pregnancy 
The epidemic of obesity is rising to an alarming level internationally (1),  affecting up to two-
thirds of the population in some developed countries.(2) Industrialised food production, 
international trade, and sedentary lifestyle are some of the factors contributing to this 
epidemic. The impact of obesity on public health is substantial. With an increased risk of 
cardiovascular disease, cancer, diabetes and metabolic disorders, the burden of obesity on 
healthcare in the UK is expected to rise to 2 billion pounds per year.(3)  
 
The prevalence of maternal obesity, in particular, is rising at a substantial rate. In the UK 
almost every other woman entering pregnancy is obese or overweight.(4) Pregnant women 
with metabolic risk factors such as obesity, dyslipidaemia and chronic hypertension are at 
higher risk of adverse pregnancy outcomes.(5) Obese mothers entering pregnancy experience 
an exaggerated physiological response characteristic of high insulin resistance, 
hyperlipidaemia, coagulation disturbance and hyper-inflammatory state.(6) This contributes 
to higher oxidative stress leading to endothelial dysfunction and abnormal trophoblastic 
functionality.(7)  
 
Mothers with metabolic risk factors are at higher risk of pre-eclampsia, gestational diabetes, 
pre-term birth and birth by caesarean section.(8) Dyslipidaemia increases the risk of 
cardiovascular disease in pregnancy and contributes to higher gestational weight gain 
irrespective of associated factors and significantly.(9) Chronic hypertension contributes to 
higher risk of pre-eclampsia, fetal growth restriction, placental abruption and preterm 
birth.(10) Developing metabolic disease in pregnancy is associated with worse long-term 




The offspring of obese mothers is also affected by the suboptimal in-utero environment 
leading to permanent changes in the offspring’s metabolism and epigenetics. The in-utero 
over-nutrition status predisposes children to neonatal complications, childhood obesity, 
diabetes, and asthma.(6) This adverse impact is spreading over many generations contributing 
to a progressive surge in maternal and childhood adiposity worldwide.(12)  
 
1.2 Lifestyle modification interventions 
The huge impact of maternal obesity on public health emphasises the demand for cheap, 
effective and scalable interventions internationally. Current guidelines by the IOM and NICE 
offer general recommendation on the optimal gestational weight gain, physical activity and 
dietary habits in pregnancy.(13,14) Only 40% of women are adherent to these guidelines and 
effective implementation is lacking.(15)  
 To date, most available pharmacological interventions such as aspirin, calcium, folic acid 
and vitamin-D had limited effect on improving pregnancy outcomes.(16) Evidence on the 
benefits of bariatric surgery for excessive obesity before pregnancy, while seems to be 
positive, remains limited.(17) Recent population studies confirms the beneficial effect of pre-
pregnancy surgery in morbidly obese women on reducing short term outcomes such as 
gestational diabetes and large for gestational age.(18,19) However, long term outcomes 
continue to be scares and the intervention could increase morbidity and antenatal 
surveillance. (19) 
 
Lifestyle and dietary interventions have potentials to reduce metabolic risk factors and 
improve pregnancy outcomes.(8) Compared to other lifestyle interventions, diet-based ones 
were associated with reduced gestational weight gain and improved pregnancy outcomes.(8)  
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In a non-pregnant population, healthy lifestyle interventions were associated with significant 
reduction in the risk of cardiovascular disease, metabolic disorders, and cancer.(20)   
Pregnancy offers an ideal window of opportunity to invoke a change in mothers’ lifestyle 
driven by the wellbeing of the baby (21) and the planned regular antenatal encounters.(22) 
Lifestyle interventions including dietary, physical and mixed interventions; can significantly 
reduce gestational weight gain in a high-risk population (8,23). However, the large variation 
in the evaluated interventions and the choice of clinical outcomes restricts meaningful 
evidence synthesis.(8)  
 
1.3 Dietary assessment tools 
Assessing dietary intake following lifestyle modification intervention is complicated in 
pregnancy due to the high inter-rater variability and the regular changes in dietary 
requirement per trimester. Many factors can affect the accuracy of dietary assessment such as 
the study design, the planned intervention, and the population characteristics. Self-reporting 
dietary assessment tools are commonly used in nutritional studies for their ease of use and 
low cost.(24) These, however, have a number of limitations that could affect their validity 
and reliability when used in a pregnant population. Choosing the right dietary assessment 
tools is essential to ensure the validity of nutritional studies. Evidence on the best suitable 
tools for use in pregnancy is inconsistent.(25) There is a need to screen current practice and 
generate guidance on the most applicable dietary assessment tools for nutritional trials in a 
pregnant population.  
 
1.4 Online health information on obesity in pregnancy 
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Patients and health professionals commonly consult the Internet for relevant health 
information in developed countries, the quality of available online sources is however, 
inconsistent (26). Poor quality information can adversely influence mothers’ behaviour in 
pregnancy leading to worse health outcomes.(27) Engaging mothers’ in the decision making 
for their health care can help to boost adherence and improve outcomes.(28) Introducing 
lifestyle interventions on a large scale is complex and requires easy, cheap and accessible 
dissemination medium. The retention of healthy lifestyle habits is quite poor beyond the life 
of a clinical trial.(21) The use of the internet and online health information dissemination is 
emerging as a potential solution.(28) The quality of online health information on obesity in 
pregnancy is unknown and a systematic assessment is warranted.   
 
1.5 Mediterranean diet 
Countries surrounding the Mediterranean sea share a common dietary regime characteristic of 
high consumption of vegetables, fruits, fish, olive oil as the main source of cooking fat and 
mixed nuts such as walnuts, almonds and hazelnuts; medium consumption of poultry, white 
meat, dairy products, and wine with meals; and low consumption of red meat, processed and 
fast food rich in animal fat. The population of south Greece and Italy has the lowest levels of 
obesity, cardiovascular disease and certain types of cancer.(29) Recent randomised trials 
confirmed the effectiveness of Mediterranean diet in reducing metabolic risk factors and 
improving health outcomes in the non-pregnant population.(30) Many studies evaluated the 
role of Mediterranean diet in improving pregnancy outcomes, however, the majority are 
small, observational studies with high risk of bias.(8) Evidence of the effect of Mediterranean 
diet on pregnancy outcomes consists mainly of observational longitudinal studies (31–34), 
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majority of which focus on gestational weight gain as a surrogate outcome (35) or on long-
term neonatal outcomes.(36,37) 
 
There is a need to evaluate the role of Mediterranean diet in improving pregnancy outcomes 
in high-risk population, its feasibility, and its effect on long-term maternal and fetal 
outcomes. Evaluating dietary based interventions in randomised trials has various 
methodological challenges.(38) Unlike drugs and medications, assessing the effect of diet on 
health outcomes is complex. Dietary trials are prone to various confounders such as the 
participants’ adherence to the dietary intervention, the assessment of dietary intake, the lack 
of blinding and the willingness to alter habitual diet.(38,39) This is further complicated in 
pregnancy due to the high intra-rater variability and the rapid change in dietary 
requirements.(40)  
 
1.6 Aim and objectives 
The objectives of this thesis are as follow: 
- To evaluate the effect of a Mediterranean-based dietary intervention on the maternal 
and fetal outcomes in a pregnant population with metabolic risk factors. 
- To explore potential methodological challenges and solution for randomised trials 
evaluating dietary interventions in pregnancy.  
- To review current practice in assessing dietary intake in pregnancy. 
- To review and evaluate available online information on the management and risks of 
obesity in pregnancy, 
- To develop and validate accurate dietary assessment tools to measure participants’ 
compliance with a Mediterranean-based dietary intervention.  
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1.7 Framing the research questions 
In table (1.1) I have highlighted the structured research questions I attempted to answer in 
this thesis.  
 




Population Intervention / test Outcome Study design 
 How to evaluate the effect of Mediterranean-based dietary intervention on maternal and fetal outcomes in a 
high-risk pregnant population with metabolic risk factors? 
 
2 Pregnant women with 
metabolic risk factors 
Mediterranean diet 
based  
Maternal and fetal 
outcomes 
Protocol of pragmatic 
randomised trial embedded 
in a cohort study 
 
 What are the methodological challenges of randomised trials evaluating dietary interventions in pregnancy 
and potential solutions? 
 
3 Randomised trials  Dietary interventions in 
pregnancy 
Methodological 
challenges and solutions  
Discussion and analysis of 
the ESTEEM trial experience 
  
 What is the quality of online information on the risks and management of obesity in pregnancy? 
 
7 Websites with 
information about 
obesity in pregnancy 
Credibility, accuracy, 
readability, content 
quality and technology 
 





 What dietary assessment tools are currently used in randomised trials evaluating dietary interventions in 
pregnancy? 
 
4 Dietary assessment 
tools in nutritional 
studies in pregnancy 
 





 What is the validity of a food frequency questionnaire and a short questionnaire to assess the dietary intake of 
pregnant women following Mediterranean diet compared to 24 hour dietary recalls? 
 






Assessment of dietary 
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Primary validation study 
 What is the effect of a Mediterranean-based dietary intervention on maternal and fetal outcomes in a pregnant 
population with metabolic risk factors 
 
6 Pregnant women with 
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CHAPTER 2  
 
EFFECT OF SIMPLE, TARGETED DIET IN 
PREGNANT WOMEN WITH METABOLIC RISK 
FACTORS ON MATERNAL AND FETAL 
OUTCOMES (ESTEEM): STUDY PROTOCOL 
FOR A PRAGMATIC MULTICENTRE 





In this chapter, I describe the protocol of the ESTEEM study which formed the basis of my 
research.  
2.1 Abstract 
Introduction Pregnant women entering pregnancy with existing metabolic risk factors are at 
higher risk of adverse maternal and fetal outcomes. Introducing a Mediterranean-based 
dietary intervention early on in pregnancy can help to modify these risks and improve 
pregnancy outcomes. There is a need to evaluate the effectiveness of a simple, targeted 
Mediterranean-based dietary intervention on improving maternal and fetal outcomes in a 
high-risk pregnant population.  
Methods and analysis The ESTEEM was designed as a pragmatic multi-centre randomised 
trial embedded in a cohort study. We recruited pregnant women who met a pre-defined 
inclusion criteria and randomised those with metabolic risk factors (BMI ≥30 Kg/m2, serum 
triglycerides ≥1.7 mmol/L, or chronic hypertension of ≥140 mm Hg systolic or ≥90 mm Hg 
diastolic blood pressure) to either receive a Mediterranean based dietary intervention or to 
routine antenatal care. Participants in the intervention group received tailored dietary advice 
and were encourage to make SMART objectives to change their diet towards a Mediterranean 
lifestyle. The primary outcome was a composite maternal outcome of pre-eclampsia or 
gestational diabetes and a composite fetal outcome of stillbirth, small for gestational age fetus 
or admission to the neonatal intensive care unit. The secondary outcomes included maternal, 
fetal, dietary, and laboratory outcomes. 
Conclusion The ESTEEM study was designed to evaluate the effectiveness of Mediterranean 
based dietary intervention on maternal and fetal outcomes in a high-risk pregnant population. 
The findings of ESTEEM will impact current practice and will be readily transferable to 




The epidemic of obesity is rapidly increasing affecting public health worldwide.(41) About 
30% of women of reproductive age are obese in the USA and the UK.(42,43) Entering 
pregnancy with metabolic risk factors significantly increase the risk of adverse maternal and 
fetal outcomes such as gestational diabetes, pre-eclampsia, stillbirth and neonatal death.(44) 
High levels of triglycerides and cholesterol, increased adiposity and dyslipidaemia are 
independent risk factors for pre-eclampsia and gestational diabetes.(45,46) This phenomenon 
is aggravated by many factors such as the poor dietary habits, sedentary lifestyle, and 
underlying genetic predisposition.(47)  
 
Dietary and physical activity interventions have shown a beneficial effect on reducing 
gestational weight gain, with varied effect on pregnancy outcomes.(8) Recent studies confirm 
the beneficial effect of Mediterranean-based dietary pattern in reducing metabolic risk 
factors.(48) The consumption of a Mediterranean diet rich in extra-virgin olive oil and nuts 
contributed to reducing cardiovascular and metabolic disease and improving health outcomes 
in a non-pregnant population.(49) Mediterranean diet in pregnancy seems to reduce the 
incidence of pre-eclampsia, gestational diabetes and fetal growth restriction.(50–52) 
However, the majority of available studies in a pregnant population are non-randomised, of 
poor quality, and focus on specific components of the diet, rather than modifying the overall 
dietary pattern.(8)  
 
There is a need for an adequately powered pragmatic randomised trial to evaluate the 
beneficial effect of a Mediterranean diet in pregnancy that is simple, feasible and targeting 




2.3 Aim and objectives 
The aim of the ESTEEM study was to assess the effectiveness of a Mediterranean diet based 
intervention in pregnant women with metabolic risk factors to improve maternal and fetal 
outcomes.  
 
The primary objective of the study was to compare, in a high risk pregnant population, the 
effect of a simple, targeted Mediterranean-based diet, supplemented with extra-virgin olive 
oil and nuts, composed within culturally appropriate recipes and food options, on a composite 
maternal (pre-eclampsia or gestational diabetes) and fetal outcome (stillbirth, small for 
gestational age fetus or admission to neonatal intensive care unit), to routine antenatal care.   
 
The secondary objectives were: to assess the effect of the dietary intervention on different 
individual maternal and fetal complications; to assess the effect of the dietary intervention on 
the participants’ lipid profile in the two randomised groups; to evaluate the risk of 
complications in women with and without metabolic risk factors in the cohort group; to study 
the effect of the dietary intervention on the risk of composite maternal and fetal outcomes in 
the following subgroups: obese women, women with raised triglycerides and women with 
chronic hypertension; and to establish a cohort for medium and long term follow-up of 
mothers and babies after birth. 
 
2.4 Methods 
2.4.1 Study design  
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ESTEEM was a randomised trial embedded in a cohort study. The study recruited in five 
large maternity units in England (Royal London hospital, Whipps Cross university hospital, 
Newham university hospital, St George’s university hospital, and the Birmingham women’s 
hospital) from September 2014 to September 2016.  
NHS Research Ethics Committee approval was obtained in all centres (UK IRAS integrated 
research application system; reference 14/EE/1048). ESTEEM is registered online with 
clinicaltrials.gov (NCT02218931). 
The inclusion and exclusion criteria for the recruitment and randomisation process in 
ESTEEM is highlighted in figure (2.4.1) 
 




2.4.2 Study conduct 
Inclusion 
•Age ≥ 16 years
•Singleton pregnancy
•Gestation age < 18 weeks
•BMI ≥ 18.5 or < 40 Kg/m2
•Understands spoken and written English
•Can consume nuts and olive oil
•Able to follow a Mediterranean dietExclusion
•History of Type 1 or Type 2 diabetes
•History of chronic renal disease or auto-
immune disease
•Taking any lipid altering drugs e.g. Statins 
Randomisation •High blood pressure at booking ≥ 140 
mm Hg systolic and/or ≥ 90 diastolic 
mm Hg 
•Serum triglycerides ≥1.7 mmol/l
•BMI ≥ 30 Kg/m2
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Pregnant women due for their first booking antenatal visit were provided with the ESTEEM 
Patient Information Sheet (Appendix 2) at least twenty-four hours prior to the hospital 
booking visit to ensure that they have adequate time to consider the trial. In case it did not 
reach a participant in advance, the ESTEEM research team introduced the trial verbally to the 
participants before completing the consent form in the antenatal clinic. Participants were 
asked to complete an additional written consent form prospectively to collect and store 
umbilical cord blood samples after delivery for use in future studies. This was not mandatory 
to join the study. Examples of both consent forms are submitted as supporting information 
(Appendix 3).  
Following consent, the research team collected the participant’s baseline information (age, 
ethnicity, socioeconomic status, access to healthy food and physical activity, smoking, 
substance misuse, pre-existing medical conditions, mental health history, obstetric history, 
family history) (Appendix 4, A), measured their blood pressure, weight, height, BMI, and 
took a venous blood sample to measure their lipid profile (triglycerides, cholesterol, HDL, 
LDL, VLDL ) and assess their suitability for randomisation. Women were eligible for 
randomisation to the trial if they have any of the following risk factors: obesity (BMI ≥30 
Kg/m2), raised serum triglycerides (≥1.7 mmol/L) (53), or chronic hypertension (≥140 mm 
Hg systolic or ≥90 mm Hg diastolic blood pressure) (Figure 2.4.1).  
 
Randomisation was performed via a password protected internet-based data management 
system in a ratio of (1:1). Minimisation (with a random element to ensure allocation 
concealment) was used to ensure balanced groups for maternal weight, gravidity, and 
ethnicity. Women who fulfil the above criteria were randomly allocated to the intervention 
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group or the control group. Women with no metabolic risk factors were allocated to the 
cohort arm to collect their maternal and fetal outcomes at the end of the pregnancy. 
 
2.4.3 Intervention 
The ESTEEM dietary intervention is based on Mediterranean diet, with education to modify 
lifestyle choices. The key components of the diet include high intake of fruit and vegetables, 
non-refined grains, legumes, moderate to high consumption of fish, small to moderate intake 
of poultry and dairy products such as yoghurt and cheese, low consumption of red meat and 
processed meat and avoidance of sugary drinks, fast food, and food rich in animal fat. In 
particular, ESTEEM advocates high intake of nuts (including walnuts, hazelnuts, and 
almonds) and high intake of extra virgin olive oil as the main source of fat (Appendix 6, A). 
 
Following randomisation, women in the intervention arm were invited to attend the ESTEEM 
antenatal clinic to start the intervention by 18 weeks gestation. All participants were 
interviewed by the ESTEEM study dietician or a trained allied health professional to assess 
their baseline diet and deliver the dietary intervention on a 1-1 basis. The dietician used a 24 
hours food recall followed by focused questions to estimate the participant’s basal dietary 
intake and identify elements for change towards a Mediterranean diet (Appendix 5, E). Once 
identified, the participants were encouraged to set and record personalised goals following 
the SMART model (specific, measurable, achievable, relevant and time-specific) to 
implement the highlighted dietary changes.(54) These goals were recorded in the 




The dietician provided basic education on the benefits of Mediterranean diet on the 
pregnancy and the drawbacks of poor adherence to the intervention. Starting at this session 
and throughout the pregnancy, women were provided with extra virgin olive oil and sachets 
of nuts (such as walnuts, hazelnuts, and almonds) and were instructed to consume 0.5 
litre/week of extra virgin olive oil for the whole family and 30 g/d of mixed nuts individually. 
The dietician also provided culturally modified cooking recipes to help the women include 
the components of Mediterranean lifestyle into their diet such as nuts and fish plus factsheets 
on the benefits of consuming these nutrients in pregnancy. 
 
Both groups of participants were asked to complete the following questionnaires by 18 weeks 
gestation: the ESTEEM questionnaire (a 12 items short dietary questionnaire specifically 
designed to assess the intake of Mediterranean food groups), the IPAQ questionnaire to 
assess participant’s physical activity (55) and the EQ-5D questionnaire to assess their quality 
of life.(56) (Appendix 5) 
 
Participants were then invited to two further intervention sessions at 20 and 28 weeks 
gestation. These sessions were delivered in a group setting including mothers and where 
possible their partners. The trial dietician delivered bespoke presentations providing basic 
dietary education, good food habits, healthy shopping advice, reading food labels, beneficial 
dietary elements in the Mediterranean diet and general pregnancy health advice. Women 
were encouraged to share their experience with the dietary changes, explore obstacles to 
adopting the intervention and potential solutions. Two follow-up phone calls were made to 
participants in the intervention group at 24 and 32 weeks gestation to check on their 
wellbeing, and assess their adherence.  
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Between 36 weeks gestation and delivery participants from both groups were invited to a 
final 1-1 follow-up session to assess dietary intake, physical activity, quality of life, repeat 
the serum lipids profile blood test, and measure their weight and blood pressure (Figure 
2.4.2). 
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Participants in the intervention group who missed the first appointment at 18 weeks, were 
given another appointment at 20 weeks of gestation. Those who attended the initial 
intervention sessions but failed to turn up to subsequent ones were kept in the intervention 
group as long as they adhered to the intervention and collected the nuts and olive oil.  
Participants who missed a group session were rescheduled within a two-week window. 
Subsequent failures to attend were recorded as a deviation of the protocol. 
 
2.4.4 Control group 
The control group were provided with the usual antenatal dietary advice as per NICE 
guidelines on antenatal care, weight management in pregnancy and hypertension in 
pregnancy.(57–59) Folic acid and vitamin D supplementation were provided as per national 
recommendations for all participants.  
 
2.4.5 Umbilical cord blood samples collection and storage 
Umbilical cord blood samples were collected from all consented participants upon delivery of 
the baby for use in future studies. Blood was collected from the umbilical cord and the 
placenta (using a syringe and a needle) and saved in a 10 mls EDTA dry tubes. All samples 
were initially stored for a maximum of 72 hours at the site of collection and were coded 
anonymously by the supervising midwife with no information identifying the study 
participants. The research team then moved the stored samples to an accredited tissue bank 
facility (The Blizard Institute – Queen Mary University of London) to be stored in -80 °C 
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freezer. Samples will be stored in accordance with the institutional Data Protection Policy for 
the lifetime of the study and 10 years after its completion. 
 
2.4.6 Outcome measures 
The primary outcome was a composite maternal outcome defined as pre-eclampsia (new 
onset or superimposed) or gestational diabetes; and a composite fetal outcome defined as 
stillbirth, small for gestational age fetus (birth weight less than 10th centile) or admission to 
the neonatal intensive care unit. (Appendix 7) The choice of composites was decided in 
consensus among the trial steering committee, the data monitoring committee, and the trial 
management team based on a Delphi survey of key stakeholders prioritising outcomes’ 
reporting for obesity in pregnancy research. (60) 
 
The secondary outcomes were  
maternal: pre-eclampsia, gestational diabetes, gestational weight gain, admission to high 
dependency unit or intensive care unit, antepartum haemorrhage, mode of delivery, preterm 
delivery (<37 weeks, and < 34 weeks), anaemia, and physical activity.  
fetal and neonatal: small for gestational age (<10th centile), very small for gestational age (< 
3rd centile ), large for gestational age (> 90th centile), stillbirths, birth weight (in Kg using 
both customised and population centiles), admission to neonatal intensive care units, neonatal 
deaths, and hypoxic ischaemic encephalopathy.  
dietary: food intake for olive oil, nuts, vegetables, fish, fruits, pulses, red meat, white meat, 
butter/margarine, sugary drinks, commercial sweets, and micronutrients.  
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laboratory:  maternal serum lipids including levels of triglycerides, high-density lipoproteins 
(HDL), the ratio of triglycerides (ratio of triglycerides to HDL ) and non-high-density 
lipoprotein cholesterol (Non-HDL, cholesterol minus HDL). 
 
2.4.7 Sample size 
We estimated the prevalence of the composite maternal and fetal outcome in our population 
at 24%. We expected the ESTEEM dietary intervention to reduce it by 30%. (8,107) To 
ensure an 80% power at the 5% significance level we needed to randomise 982 women. We 
increased the target sample size to 1230 women to allow for a 20% dropout rate.  
 
2.4.8 Statistical analysis 
2.4.8.1 Primary analysis 
Participants who were enrolled in error or failed to consent were excluded post 
randomisation. We included those who withdrew their consent unless they specified 
otherwise. The primary analysis was conducted on intention-to-treat (ITT) for all reported 
outcomes. Non-adherent participants were included in the ITT.  
 
Baseline demographics and clinical characteristics were summarised as percentages for 
categorical variables, mean (standard deviation) for parametric continuous variables, and 
median (interquartile range) for non-parametric ones.  
 
We reported the intervention effect on the risk of composite maternal and fetal outcomes as 
an odds ratio with 95% confidence interval, using a multivariable logistic regression. We 
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adjusted for the minimisation factors, as well as age, history of previous gestational diabetes, 
family history of hypertensive disorders (hypertension and/or pre-eclampsia), family history 
of diabetes, history of stillbirth and the recruitment centre. These covariates were selected 
based on prior evidence. We reported crude and adjusted odds ratios with 95% confidence 
intervals. Post randomisation miscarriage or medical termination of pregnancy were excluded 
from all analyses of the primary composite fetal outcome. 
 
A secondary analysis for the primary outcome was performed accounting for the participants’ 
adherence to the intervention using a complier-averaged causal effect (CACE) analysis.(16) 
We used generalised latent variable modelling via the ‘gllamm’ command in Stata to estimate 
the CACE adjusting for covariates.(17) Adherence to the intervention was assessed primarily 
against the number of sessions attended (at 14-18, 20 and 28 weeks gestation), and if needed 
supplemented with dietary information collected using the ESTEEM Questionnaire.  
 
2.4.8.2 Subgroups and secondary outcomes analysis 
We repeated the primary ITT analysis for the primary composite outcome in each of the 
following subgroups: women with obesity (BMI ≥ 30 Kg/m2), with raised triglycerides (≥1.7 
mmol/l), and with raised blood pressure (systole ≥140mm Hg or diastole ≥ 90 mm Hg). We 
reported specific subgroup odds ratios with 95% confidence intervals and tested for an 
interaction term. 
 
Secondary outcomes were analysed using a multivariable logistic regression for binary 
outcomes and a linear regression for continuous outcomes, with a normalising transformation 
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where necessary. Where a continuous outcome was also assessed at baseline, this was 
adjusted for as an additional covariate. Preterm delivery was analysed as a binary indicator 
for preterm delivery (<37 weeks) and early preterm delivery (<34 weeks). Mode of delivery 
was dichotomised into vaginal delivery vs. caesarean section and analysed as a binary 
variable. We used separate logistic regression models within vaginal deliveries and caesarean 
section to compare normal vaginal delivery to instrumental vaginal delivery and elective 
caesarean section to emergency caesarean section, respectively.  
We used the GROW centile charts to calculate birth centiles and determine the incidence of 
small, very small and large for gestational age.(61) Population centile charts were used in an 
additional sensitivity analysis adjusting for gestational age only. We used the Metabolic 
Equivalent of Task method to estimates the minutes/week physical activity from the IPAQ 
questionnaire as a continuous outcome.(18) 
 
The study statistician and the chief investigator remained blinded to not bias the analysis and 
interpretation of results. Unblinded summaries and reports using computer code were 
provided to the Data Monitoring Committee (DMC) by an independent statistician from the 
PCTU. All analyses were conducted using STATA version 12 or higher (StataCorp, College 
Station, TX, 2012).  
 
2.4.8.3 Missing data 
We did not anticipate any missing primary outcome data, as the selected outcomes should be 
recorded for all women and newborn infants. Minimisation factors were essential to 
randomise participants and no missingness was expected. We used mean imputation or a 
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missing indicator for continuous and categorical variables to compensate for any missed 
baseline covariates. 
Only participants with complete outcome measures at baseline were included in the analysis. 
This approach is unbiased if the data were ‘Missing at Random’ i.e. missingness for the 
outcome is related to the observed covariates. We planned to conduct a sensitivity analysis if 
>5% of data for the primary outcome is missing to explore the missing at random 
assumption. The analysis for secondary outcomes included participants with complete 
outcome data only.   
 
2.4.9 Food frequency and ESTEEM questionnaires 
To assess the dietary intake of participants in the randomised trial we used a specially 
developed food frequency questionnaire (FFQ) and a short 12 items questionnaire (the 
ESTEEM Q) relevant to Mediterranean diet (Appendix 5). Details on the development and 
the validation of these questionnaires are discussed in chapter (6).  
 
2.4.10 Internal pilot 
We performed an internal pilot in the first 3 months of the study to evaluate the rates of 
recruitment to the trial and test its procedures. We sought feedback from service users on the 
design of the patient information materials during the first three months of the study setup 
phase. We also assessed the number of pregnant women screened for recruitment and the 
ratio of those who were eligible for randomisation. We examined the participants’ reasons for 
declining recruitment, withdrawing from the trial and deviating from the protocol.  
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We planned to survey the clinical staff at the end of the pilot phase if we failed to recruit 
>50% of forecasted eligible women to identify any issues affecting recruitment. Similarly, we 
planned to review the feasibility of the trial if we failed to recruit >50% of the target 
population within the first 6 months of the trial. 
 
2.4.11 Trial committees  
ESTEEM has a Trial Steering Committee (TSC) formed of four independent members, 
including a representative from Action on Pre-eclampsia, a charity dedicated to the wellbeing 
of women diagnosed to have pre-eclampsia, and a service user with a history of pre-
eclampsia. The TSC provided independent supervision for the trial conduct in the form of 
advice to the Co-Investigators and the sponsor on all aspects of the trial. The TSC ensured 
that the trial is conducted according to the principles of Good Clinical Practice in Clinical 
Trials and that all participants were recruited to the trial safely. All planned protocol 
amendments were discussed and approved by the TSC, Main REC and the sponsor before 
implementing them.   
An independent Data Monitoring Committee (DMC) was formed to review updates on the 
results and the study progress. Interim analyses of safety and study outcomes were provided 
to the DMC in strict confidence by an independent statistician from the PCTU. The DMC 
advised the chair of the TSC if, in their view, the trial should stop on safety grounds, or if any 
protocol modifications were needed. 
  
2.4.12 Data handling and confidentiality 
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The Chief Investigator had the overall responsibility to ensure that the participants’ 
anonymity is protected and maintained at all times in the study. All information collected on 
the study participants were kept confidential and managed in accordance with the Research 
Governance Framework for Health and Social Care, the Data Protection Act (1998-UK), the 
NHS Caldicott Guardian (Health Service Circular: HSC 1999/012), and the Research Ethics 
Committee (REC) Approval. 
 
All data collected in the study were entered by the research team onto a dedicated password 
protected electronic database hosted on the PCTU server using a secure computer and 
internet connection. The staff stored all collected paper case report forms (CRF) as a backup 
at each site. We performed regular monitoring on collected data checking for consistency, 
viability, quality and out-of-range errors. Any missed or incomplete records were sent back to 
the relevant study site to cross check against paper-based forms.  
 
All collected data were anonymised prospectively to ensure the participants’ confidentiality.  
Disclosure of personal information was not permitted to any third party without appropriate 
approval by the sponsor. All records will be kept securely by the sponsor for a further 20 
years upon completing the study.  
 
2.4.13 Auditing and quality assurance  
The Chief Investigator had the overall duty to ensure that the trial is conducted in compliance 
with all applicable regulatory requirements including but not limited to the principles of the 
Declaration of Helsinki (1996), the Research Governance Framework, Good Clinical 
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Practice, local research office policies and procedures, and any subsequent protocol 
amendments. 
We employed a number of interventions to capture non-compliance including monitoring 
visits, regular auditing, site communications, and updates. All recruiting sites performed 
remote data monitoring including random cases checking to ensure data validity. Any major 
discrepancies found during the site visits were recorded and escalated to the sponsor.  
The sponsor kept a log of any non-compliance to capture any trends developing or escalating. 
Any issues were resolved by the trial team within a time frame fixed by the sponsor.  
 
2.4.14 Adverse Events 
Adverse events were defined as any unfavourable and unintended sign (including abnormal 
laboratory findings), symptom or disease temporarily associated with study activities. Serious 
adverse events were defined as any unexpected incidence of death, life-threatening condition, 
hospitalisation (including prolongation of existing hospitalisation), disability or incapacity 
(persistent or significant), congenital anomaly or birth defect, or any condition judged as 
medically significant by the investigator 
The incidence of any adverse event was recorded in the participant’s individual study file, the 
medical notes, and the CRF and was followed up by the research team appropriately. Serious 
adverse events were reported within 24 hours of noticing the event to the sponsor and within 
15 days to the main research ethics committee.  
 
2.4.15 Dissemination of study findings 
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Delivering the ESTEEM study successfully was possible thanks to the hard efforts of a large 
team of stakeholders including doctors, nurses, midwives, nutritionists and others. The 
success of publishing the study’s results will be dedicated to and shared among all 
collaborators equally.  
The trial management committee is responsible for publishing the ESTEEM findings in high 
impact open access peer-reviewed journals where possible. Recruiting centres were not 
permitted to publish partial data obtained from participants in the ESTEEM study without 
discussion with the Chief Investigator and/or the TSC. 
 
2.5 Conclusion  
The ESTEEM study is designed to evaluate the effectiveness of Mediterranean based dietary 
intervention in a high-risk pregnant population on maternal and fetal outcomes. The findings 
of ESTEEM will impact current practice and will be readily transferable to clinical settings.   
 
This chapter led to the following publication: 
Al Wattar BH, Dodds J, Placzek A, Spyreli E, Moore A, Hooper R, Beresford L, Roseboom 
TJ, Bes-Rastrollo M, Hitman G, Khan KS, Thangaratinam S. Effect of simple, targeted diet in 
pregnant women with metabolic risk factors on maternal and fetal outcomes (ESTEEM): 
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In this chapter, I discuss the various methodological challenges and the lessons learned from 
the ESTEEM study.  
 
3.1 Abstract 
Introduction Evaluating complex dietary interventions in randomised trials involves unique 
methodological challenges relevant to the nature of the intervention, the target population and 
assessing participants’ adherence. ESTEEM was a randomised trial evaluating the 
effectiveness of a Mediterranean-based dietary intervention on maternal and fetal outcomes 
in a high-risk pregnant population. Here we discuss the various methodological challenges 
and the solution applied during the ESTEEM study. 
Methods We screened and recruited pregnant women at their first booking appointment 
against our predefined inclusion criteria. Participants with metabolic risk factors were 
randomised to either a Mediterranean-based dietary intervention or routine antenatal care. 
The intervention was delivered by the trial dietician over three sessions at 18, 20 and 28 
weeks gestation. The primary outcomes was a composite maternal outcome of pre-eclampsia 
and/or gestational diabetes and a fetal composite outcome of stillbirth, small for gestational 
age fetus and/or admission to the neonatal intensive care unit. 
Challenges and solutions There were five key challenges encountered in ESTEEM, 
recruiting participants, delivering the intervention, engaging the clinical staff at recruiting 
centres, assessing the participants’ adherence and finally deciding on the primary outcome 
measures. We improved the recruitment rate to ESTEM by increasing the number of 
participating centres and prolonging the recruitment period. We introduced a number of 
educational interventions to engage clinical midwives and other healthcare providers at each 
site. We delivered the intervention early on in the pregnancy to promote the dietary effect on 
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healthy placentation and reduce metabolic risk factors. We encouraged our participants to 
attend the intervention group sessions with their partners and involve the whole family with 
the dietary intervention to improve adherence. We developed and validated a short user-
friendly dietary questionnaire to assess the intake of key foods in the Mediterranean diet. We 
defined the study composite primary outcome in consensus based on input from a panel of 
experts on dietary research in pregnancy. 
Conclusion The ESTEEM experience offers an insight into future pragmatic nutritional 






Dietary and lifestyle interventions have been the focus of much research recently to improve 
health outcome and combat the obesity epidemic.(8,62) The effect of Mediterranean diet, in 
particular, is shown to reduce metabolic risk factors and cardiovascular disease.(63–65) 
However, the evidence on its effectiveness to improve pregnancy outcomes remains 
limited.(23,62) 
Evaluating complex dietary interventions in a pregnant population poses unique 
methodological and conceptual challenges.(38,40) The validity of nutritional studies can be 
undermined by many variants such as the participants’ adherence to the intervention, the 
variation in the dietary requirement in pregnancy and the choice of outcome measures.(66) 
We undertook a multicentre randomised trial (ESTEEM) to assess the effectiveness of a 
Mediterranean-based diet intervention to improve health outcomes in pregnant women with 
metabolic risk factors. In this chapter, I highlight the methodological challenges and the 
lessons learned from the ESTEEM study. 
 
3.3 Methods 
ESTEEM was designed as a randomised trial embedded in a cohort study. The study ran from 
September 2014 till September 2016 in five tertiary maternity units in the UK. The inclusion 
and exclusion criteria are highlighted in figure (2.4.1). The primary outcome was a composite 
maternal outcome defined as pre-eclampsia (new onset or superimposed) or gestational 
diabetes; and a fetal composite outcome defined as stillbirth, small for gestational age fetus 




The ESTEEM dietary intervention is based on the Mediterranean diet lifestyle (Appendix 6, 
A). The intervention was introduced by a series of dietary education sessions providing 
individual dietary advice towards a Mediterranean diet, grocery shopping advice, cooking 
recipes for a healthy diet and advice for appropriate meal choices at restaurants. 
Participants were also consented to collect umbilical cord samples after delivery to be used 
for future research on the effect of the dietary intervention on fetal biochemical outcomes.  
We aimed to randomise 1230 women with metabolic risk factors to detect a 30% reduction in 
the primary maternal and fetal outcomes and maintain an 80% power at the 5% significance 
while allowing for a 20% dropout rate.  
 
3.4 Challenges and solutions 
3.4.1 Recruitment  
We initially estimated a 14-months period to achieve the recruitment target. However, based 
on the pilot analysis we detected a slower than expected recruitment rate. We resolved to 
increase the number of recruitment centres from three to five major tertiary maternity units 
and extend the recruitment period by four months. Establishing and managing multiple 
recruitment centres requires significant investment in resources. In view of the limited 
funding, we planned a stepwise opening and closer of the ESTEEM recruiting centres to 
troubleshoot local challenges and allocate resources accordingly. This helped to ease off the 





To help deliver the intervention and the follow ups, we rolled out a series of evidence-based 
measures aimed to embed the trial conduct into clinical practice at the every recruiting 
centre.(68) We delivered a series of research training sessions targeting clinical midwives to 
enable them to recruit and consent participants during their booking sessions in the antenatal 
clinic. We supplemented these with a series of talks and interactive sessions for all the 
clinical staff and healthcare providers to emphasise the benefits of involving patients in 
clinical research. We complemented the top recruiting midwives at each of the sites offering 
acknowledgment certificates, institutional staff newsletters promotions in addition to small 
financial incentives and vouchers. Overall clinical midwives consented a third of participants 
recruited into ESTEEM.   
 
We deployed posters, stands, and leaflets at every antenatal booking reminding clinical staff 
to approach women to join ESTEEM. We also attached an additional ESTEEM eligibility 
sheet to all booking clinical notes. The ESTEEM research team maintained daily presence at 
recruiting antenatal clinics to support clinical staff and boost recruitment. Participants who 
required additional time to consider the trial before consenting were followed up with 
telephone calls by the research team.  
 
3.4.2 Intervention delivery and Engagement 
Maximising the exposure to the dietary intervention is likely to improve its effectiveness 
inducing healthier in utero conditions and reducing existing metabolic risk factors.(69) This 
promoted us to deliver the intervention early on in pregnancy by 18 weeks gestation. 
Unfortunately, this was not always feasible, as many participants were not able to attend their 
initial appointment. To improve our retention rate we decided to reschedule non-attenders 
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extending the intervention window till 20 weeks gestation. Typically all booking women 
attend a 20 weeks ultrasound scan as per the NICE antenatal care guideline (59) which helped 
us to maximise the number of participants in the intervention arm. Data from our pilot phase 
suggested that participants are more likely to continue in the trial if they attended the first 
planned session.  
 
Participants’ culture and dietary habits are major confounders in nutritional trials, particularly 
in pregnant women.(70) Engaging participants in the planning of the intervention is advised 
to promote belief and adherence to the intervention.(71) Certain food groups are culturally 
more emphasised in pregnancy (72) and mothers are also more likely to follow advice from 
friends and family members, compared to health care professionals.(73) Interactive 
interventions based on the social cognitive theory are effective to improve adherence to 
lifestyle intervention on the longer term.(74) We encouraged our participants to set up their 
own SMART objectives (specific, measurable, achievable, relevant and time-specific) and 
dietary goals towards a Mediterranean lifestyle. This was aimed to engage participants in the 
intervention and improve adherence. We involved partners and the whole family where 
possible particularly in larger families where pregnant women may not do the cooking and 
the shopping for the entire household. We delivered a number of educational sessions to 
boost the participants’ basic nutritional knowledge and emphasise the benefits of 
Mediterranean diet to both mother and baby.  
Some of the key elements in the Mediterranean diet, namely extra virgin olive oil and mixed 
nuts, were relatively expensive to purchase locally by our participants. The high-cost element 
could reduce consumption and affect adherence.(75) This prompted us to provide supplies of 




We planned the following two intervention sessions (at 20 and 28 weeks) in a group setting 
of the participants and their partners. The aim of these sessions was to provide further 
knowledge on the benefits of Mediterranean diet, share experiences, success stories and 
explore obstacles to adhering to the intervention. The sessions also included bespoke 
educational presentations on reading food labels plus advice on healthy shopping habits and 
shared grocery lists.  
 
Poor attendance often reduced the group size to one or two participants only. For those 
participants who missed a session or two, we attempted to reschedule or arranged to send 
them the nuts and extra virgin olive oil by post to ensure they maintained their intake and 
compliance with the intervention.  
 
3.4.3 Assessment of dietary intake 
Estimating the participants’ dietary intake at baseline and after delivering the intervention is 
an integral requirement in nutritional studies.(38) In pregnancy, dietary assessment is 
complicated by the increased inter-rater variability and the constant change in dietary 
requirements.(40) The population characteristics can also influence the dietary assessment 
process; our population consisted mainly of multiparous women, often from a transiently 
immigrant background. Many of them had low literacy of English language, were in full-time 
employment or looked after larger families. Considering these factors we needed a short, 
sensitive and user-friendly assessment tool.   
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Our dietician used a 24-hour dietary recall coupled with the multi-pass technique (76) and a 
series of focused open-ended questions to assess the participant’s baseline dietary habits. This 
enabled our dieticians to identify areas for improvement and the necessary changes towards 
adopting a Mediterranean based diet. 
 
Following on discussions among the ESTEEM management committee, we decided to use a 
modified food frequency questionnaire (FFQ) and a short 12-items questionnaire (ESTEEM 
Q) (Appendix 5) to assess adherence throughout the trial. Details on the development and 
validation of these tools are discussed in chapter (6). 
Using the FFQ proved less popular than expected. Only 30% of our participants in the control 
group completed and returned their FFQ’s after randomisation. Adopting a pragmatic 
approach, we decided to use the FFQ for validation purposes only and aborted its use later on 
in the trial.  
  
We used the ESTEEM Q as a measure of adherence secondary to the number of attended 
sessions. We identified 12 semi-quantified questions relevant to the Mediterranean diet 
coupled with 7 dichotomous questions on conditions specific to pregnancy that could affect 
the participants’ dietary intake. We modified a similar questionnaire that was validated for 
use in a non-pregnant population following a Mediterranean based dietary intervention.(77)   
We asked our participants to retain and return empty packets of consumed nuts and extra 
virgin olive oil as another marker of adherence. However, due to the poor return rate, we 




Initially, we planned to use specific biomarkers to objectively assess the intake of key food 
items in addition to completing the self-reporting dietary questionnaires. Alpha-linolenic 
acids and hydroxytyrosol are two commonly used serum biomarkers to assess the intake of 
nuts and olive oil in nutritional studies.(78) Our hypothesis was to increase the intake of 
unsaturated fatty acids by increasing the consumption of these two food items particularly as 
well as other elements of the Mediterranean diet. Thus, objectively assessing the intake of 
nuts and olive oil would support the validity of our findings. However, measuring these 
biomarkers involves high cost and significant staff involvement. Furthermore, collecting 
numerous serum samples for trial use only is invasive and could put off participants from 
continuing the trial.(78)  
Considering all these factors our main measure of adherence was the number of attended 
intervention sessions supplemented with scores derived from the ESTEEM Q.  
 
3.4.4 Control group selection 
Setting up an appropriate control medium is often complicated in nutritional studies due to 
the large variation among participants.(79) Establishing the efficacy of specific food items 
requires the introduction of an appropriate control diet or the withdrawal of evaluated food 
items from the comparison group.(80)  
The objective of ESTEEM was to evaluate the effectiveness of the dietary intervention as a 
whole in routine clinical settings. Adhering to this pragmatic approach, we did not employ 
any dietary restrictions on the participants in the control arm. This will emphasise the 
external validity of ESTEEM findings making it directly transferable to clinical settings. 
This, however, comes with certain limitations. The ESTEEM population was ethnically 
diverse encompassing multiple food cultures and dietary habits; some of the participants in 
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the control arm might already follow a Mediterranean lifestyle. ESTEEM was a non-blinded 
trial; while no interaction was planned between the two groups, it is plausible that some 
control subjects might have adopted certain food items in the Mediterranean diet such as 
extra virgin oil. Variations in food intake among participants were inevitable, particularly as 
many of them were from transiently immigrant families adopting new food habits. 
 
3.4.5 Assessment of outcomes  
Our focus in ESTEEM was to assess the effectiveness of the dietary intervention on the 
maternal and fetal outcomes relevant to clinical practice. To date, a large number of 
nutritional trials in pregnancy focused on evaluating gestational weight gain with fewer trials 
focusing on particular maternal or fetal outcomes.(8) Detecting a significant difference in 
clinical outcomes often requires a large sample size which was not always feasible.(81) In 
ESTEEM, we sought advice from a large panel of experts on obesity in pregnancy research 
and used a multi-stage modified Delphi survey to generate consensus on the most relevant 
outcomes.(60) Both gestational diabetes and pre-eclampsia were prioritised for maternal 
outcomes in addition to stillbirth, small for gestational age and admission to NICU for fetal 
outcomes. Our trial steering committee advised to include these important measures in one 
composite maternal/fetal outcome in addition to reporting on each of theme independently as 
secondary outcomes. The large sample size recruited to ESTEEM will ensure enough 
confidence to detect a significant difference in the intervention group and reduce type 1 error.  
Reporting on changes in dietary outcomes from baseline to delivery is an important element 
in ESTEEM. As our primary assessment tool for the dietary intake was the ESTEEM Q, we 
were only able to report on the changes of major food groups’ intake with no information on 




Collecting outcomes at delivery was logistically challenging within the allocated time 
window. We nominated a dedicated team member for every recruiting site to screen the 
labour and postnatal wards daily and crosscheck new deliveries against our electronic 
records. This helped to reduce the loss to follow-up rate and ensure complete recording of 
outcomes.    
 
Our objective to collecting cord blood samples for future research also proved more 
complicated than planned. A significant proportion of our participants declined to take part in 
this aspect of ESTEEM. Collecting and freezing the samples appropriately was logistically 
challenging due to staff and resources limitations. We sought help from clinical midwives on 
the delivery suite to assist in collecting cord blood samples upon delivery and save them on 
labour ward. We identified consenting mothers by adding a special ESTEEM stickers to their 
maternity notes to remind the supervising clinical midwife (Table 3.4.5.1). 
 
Table (3.4.5.1): Summary of encountered challenges and applied solutions in ESTEEM. 
Domain Challenge Solution 
Recruitment Large sample size and 
slow recruitment rate 
Extended recruitment by 4 months and 
opened more recruitment centres. 
 
  Engaged clinical staff in the recruitment and 
follow-up process 
 
  Assigned dedicated research staff to screen 
antenatal clinics daily 
 
Delivery of the 
intervention 
Poor attendance to initial 
intervention sessions 






engagement with the 
study 
Various food cultures and 
dietary habits among 
participants 
Tailored intervention based on individual 
food habits assessment 
 Improve adherence to the 
intervention 
Actively engaged participants and their 
families in planning the required dietary 
changes to comply with the intervention 
 
  Provided group dietary educational sessions 
 
  Provided nuts and extra virgin olive oil 
throughout the pregnancy 
 
Adherence to the 
intervention 
Assessing basal dietary 
intake 
Used of a multi-pass 24-hour dietary recall 
with focused questions 
 
 Choice of dietary 
assessment tool 
Developed and validated a user-friendly 
short dietary questionnaire specific to 
Mediterranean diet 
 
Control group Choice of control 
participants 
Adopted a pragmatic approach with no 
specific dietary requirement in the control 
group 
 
Outcomes Choice of primary 
outcome 
Developed a composite outcome of maternal 
and fetal outcomes prioritised by a panel of 
experts. 
 
 Complete outcome 
collection 
Assigned dedicated research staff to screen 
postnatal and labour ward and crosscheck 
participants against electronic records 
 
3.5 Discussion 
The dietary intervention in ESTEEM was focused on improving maternal intake of key food 
items rich in unsaturated fatty acids such as nuts, fish, and extra virgin olive oil.  
Our hypothesis was that a high intake of unsaturated fatty acids can reduce oxidative stress 
and insulin resistance in pregnancy which can improve the endothelial function lowering the 
incidence of metabolic disease namely gestational diabetes and pre-eclampsia.(82) Improving 
the metabolic status can also ameliorate the in-utero conditions leading to better placentation 
and normal birth weight.(50)  
66 
 
Our knowledge on the distribution of fatty acid in pregnancy and the associated metabolic 
changes remains limited.(83) Unlike lean pregnant women, obese mothers tend to develop 
higher levels of plasma lipids such as triglycerides and very low-density lipoprotein 
compared to static levels of unsaturated fatty acids.(84) The effect of this unbalanced ratio on 
the in-utero environment and fetal outcomes also remains unclear. Comparing biochemical 
outcomes between the high risk and low-risk groups in ESTEEM will clarify the role of diet 
to improve the metabolic profile in pregnancy.  
 
Adding a qualitative aspect to nutritional studies is also important to explore mothers’ beliefs 
and attitude towards changing their lifestyle before, during and after pregnancy.(85) In 
ESTEEM we conducted a number of semi-structured interviews with mothers and their 
partners in the randomised groups to assess satisfaction and potential obstacles to adopting 
the Mediterranean diet.  
 
The adverse effect of maternal obesity on long-term maternal and fetal outcomes is well 
established; entering pregnancy as obese is associated with increased risk of developing type 
2 diabetes, cardiovascular disease and childhood asthma. (86,87) Our randomised cohort will 
offer a follow-up medium to study the effect of the dietary intervention on long-term health 
outcomes. Dietary studies are often restricted to the pregnancy period offering little insight on 
the maintenance of the intervention in the postpartum period and beyond.(62) Advances in 
dietetics’ technology can simplify data collection in future studies. The use of mobile apps 
and internet-based interventions has been reported to be helpful in maintaining diabetic 
control and studying the effect of diet on other chronic diseases.(88,89) Such methods could 
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Evaluating dietary and lifestyle interventions in pregnancy involves a number of 
methodological challenges. The ESTEEM experience offers an insight into future pragmatic 
nutritional studies in pregnancy. 
 
This chapter led to the following publication: 
Al Wattar, B.H., Dodds, J., Placzek, A., Spyreli, E., Moore, A., Hooper, R., Beresford, L., 
Roseboom, T.J., Bes-Rastrollo, M., Hitman, G. and Khan, K.S. Thangaratinam S. 
Mediterranean diet based intervention in pregnancy to improve maternal and fetal outcomes: 
Methodological challenges and lessons learned from the multicentre ESTEEM study. 








ONLINE HEALTH INFORMATION ON 





In this chapter, I have conducted a systematic review of available online information on 
prevention, risks, and management of obesity in pregnancy in English. I have assessed the 
quality of available information looking into the credibility, the accuracy, the readability, the 
content quality and the technological quality of included websites to assess the role of the 




Objective To assess the quality of health information available online for healthcare users on 
obesity in pregnancy and evaluate the role of the internet as an effective medium to advocate 
a healthy lifestyle in pregnancy.  
Study design We used the poly-search engine Polymeta and complimented the results with 
Google searches (from inception till July 2015) to identify relevant websites. All open access 
websites in English providing advice on the risks and management of obesity in pregnancy 
were included. Two independent reviewers assessed the quality of information provided in 
each of the included websites for credibility, accuracy, readability, content quality and 
technology. We compared websites’ quality according to their target population, health topic, 
and source of funding. 
Results Fifty-three websites were included. A third of websites were focused on obesity in 
pregnancy and two-thirds targeted healthcare users. The median value for the overall 
credibility was 5/9, 7/12 for accuracy, 57.6/100 for readability, 45/80 for content quality and 
75/100 for technology. Obesity-specific websites provided lower credibility compared to 
general health websites (p=0.008). Websites targeting health users were easier to read 
(p=0.001). Non-governmental funded websites demonstrated higher content quality 
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(p=0.005). Websites that are obesity focused, targeting health users and funded by non-
governmental bodies demonstrated higher composite quality scores (p=0.048).   
Conclusion Online information on obesity in pregnancy is varied, more work is needed to 
standardise and improve the quality of reporting of online health information on this topic. 
Governmental bodies in particular need to invest more efforts to improve the quality of online 







The fast spread of obesity continues to be a major health challenge internationally.(91) The 
incidence of obesity is rising in all age groups particularly in women of childbearing age.(5) 
This is affecting up to a third of pregnant women in western countries such as the USA (34%) 
and the UK (25%).(92) Entering pregnancy with a high BMI increases the risk of maternal 
and fetal complications such as gestational diabetes, pre-eclampsia, stillbirth and cesarean 
section.(5) The chief Medical Officer of England has emphasised the importance of 
encouraging women of reproductive age to adopt a healthier lifestyle before pregnancy.(93)  
 
The widespread of the Internet has facilitated the sharing and dissemination of health 
information in developed countries.(94) Internet-based platforms can host effective, cheap, 
innovative and widely accessible interventions to improve health outcomes.(93) These are 
especially applicable to chronic and long-term disease such as obesity and diabetes.(95)  
The quality of health information provided online for healthcare users, in general, is 
inconsistent.(26) Disseminating poor quality health information over the internet can be 
confusing and counterproductive leading to worse health outcomes.(96,97) 
The quality of health information available online on the risks and management options for 
obesity in pregnancy is not known. We systematically evaluated the quality of online 
information on the topic of obesity in pregnancy.  
 
4.3 Methods 
This study was conducted following a prospective protocol (CRD42015020192) and reported 
the findings in accordance with the PRISMA statement.(98) (Appendix 12) 
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4.3.1 Identification of websites 
We performed Google searches to produce a comprehensive list of search terms and identify 
internet websites providing information on obesity in pregnancy (Appendix 11).  We used the 
poly-search engine Polymeta (https://polymeta.com/) to search the following search engines 
simultaneously: Google, Ask, Yahoo, Bing, and Blekko from inception till July 2015. We 
complimented the findings with searches in Google using the different portals of English 
speaking countries such as google.com; google.co.uk; google.com.au; google.ca; and 
google.co.nz. We screened the first 10 pages arbitrarily of every search, compiled the results 
in one electronic database and removed duplicates. We included all websites in English 
reporting information relevant to obesity in pregnancy. We excluded websites with no open 
access and those with password protected content. We also excluded websites solely 
replicating scientific articles or clinical guidelines. 
 
4.3.2 Quality assessment 
We assessed the included websites for their quality of information and technology in 
duplicate. We divided the websites into categories depending on their target population 
(healthcare users vs general population), health topic (obesity-specific vs general health) and 
source of funding (governmental, commercial and non-governmental (NGO)). Websites or 
blogs started or maintained by patients and health charities were classed as NGOs. Websites 
hosted by public health organisations such as the National Health Service were classed as 
governmental.  
 
4.3.3 Information quality 
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We assessed the information provided on the website for its credibility, accuracy, readability 
and content quality. We scored the inspired credibility based on the content relevance, 
information source, utility, currency, hierarchy of evidence, editorial review process, 
statement of the original source, availability of a disclaimer (including details on ownership, 
sponsorship, funding and advertising), omissions and a mechanism for feedback. A score of 0 
or 1 was given for each item if absent or present respectively.(99)  
 
We evaluated the accuracy of provided information against peer reviewed published 
guidelines (100) (101) on pre-conception counselling, prenatal diagnosis, antenatal maternal 
risks, fetal risks, intrapartum complications and the role of diet and physical activity in 
pregnancy. Each of these items was assessed if not reported, briefly reported or reported in 
sufficient detail given a score of 0, 1 or 2 respectively. 
 
We assessed the readability of websites using an online readability calculator (readability-
score.com), using the Flesch Reading Ease test. Easy to read texts had higher readability 
scores from 0 to 100.(102) We used the DISCREN tool to evaluate the websites’ content 
quality.(103) This validated tool was composed of 16 items including the assessment of 
sources of bias, an adequate description of the benefits and risks of reported treatments, and 
the advocacy of shared decision making with patients. We gave a score to each of these items 
ranging between 1 if completely not mentioned and 5 if mentioned in sufficient detail.  
 
4.3.4 Technological quality 
We used the Nibbler software to evaluate the overall technological quality of the included 
websites (nibbler.silktide.com). Each website was assessed for its accessibility (such as ease 
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of locating information on the website, page titles, and URL format), the rated user 
experience (such as the content value, mobile availability, the content format, quality of 
internal links etc.), the marketing (links to social media, meta tags, popularity, freshness etc.) 
and the quality of informatics used (such as quality of headings, titles, images, printability 
etc.). Scores ranged between 0 and 100 for each criterion with an overall score out of 100.   
 
4.3.5 Data analysis 
We used intra-class correlation coefficients (ICC) to assess the agreement between the two 
assessors’ quality scores. We judged the agreement to be poor for a score less than 0.2, good 
for a score between 0.6 and 0.8, and very good for a score greater than 0.8.(104) We used the 
mean of the two assessors’ scores for the quality analysis. We reported parametric data using 
means and standard deviations, and for non-parametric data we reported medians and ranges. 
We standardised the scores for each domain to a mean of 0 and a standard deviation of 1 in 
order to generate a composite quality score for each website.  We used the following formula 
to generate Z score (z = (x – μ) / σ) where μ is the mean of each sample and σ is the standard 
deviation. We generated composite quality score for each website by calculating the mean of 
the calculated Z scores for each quality domain (composite score = Z scores (credibility+ 
accuracy+readability+content quality+ technological quality)/5).     
 
We used the Kolmogorov–Smirnov and the kruskal-wallis one way ANOVA tests to compare 
the different quality scores among websites according to their target users, health topic, and 
source of funding. We used the Student-T and the oneway ANOVA tests to compare the 
composite quality mean scores among these groups. We performed a post-hoc multiple 
comparison test for statistically significant between-group results using the Least Significant 
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Difference tests (LSD). We tested the association between the composite quality score and 
the funding source using a linear regression model and accommodated for the websites target 
users and the topic of focus.  
 
4.4 Results 
4.4.1 Characteristics of websites 
We identified 1169 potentially relevant websites. We excluded 652 websites on initial 
assessment and assessed 517 websites in full. Only 53 of these met our inclusion criteria and 





Figure (4.4.1): Flow chart of the selection and inclusion process for websites providing 




















About 30% of included websites were dedicated to obesity in pregnancy (17/53, 32%) and 
two-thirds targeted women and healthcare users (37/53, 70%). About half of these websites 
were American (27/53, 51%) and a third were British (17/53, 32%). Only seven websites 
provided an open access forum for users to discuss health-related information (7/53, 13%). 
Websites identified from 
Polymeta search engine 
n= 1169 
Websites identified from Google 




following initial assessment 
n= 1142 
- Articles only n=61 
- Forums/blogs n=16 
- Pregnancy generic 
n=783 






Websites that did not meet 
our inclusion criteria 
n= 27 
-No information on 
obesity in pregnancy =19 
-Not free access = 2 
- Duplicates = 6  
 
 
Websites assessed fully 
n= 80 
 






Fifty seven percent of included websites displayed a privacy statement (30/53, 57%) and 
more than a third had nominated authors and an editorial panel (21/53, 40%). We identified 
12 commercial, 18 governmental and 23 NGO funded websites. Table (4.4.1) summarises the 
characteristics of included websites. There was a very high agreement between the quality 
scores of the two assessors (ICC= 0.92). 
 
Table (4.4.1): Characteristics of included websites.  
 

















aafp.org USA No No Yes No Yes NGO 0.16 
acog.org USA No Yes No No Yes NGO 0.53 
babycenter.com USA No Yes Yes No Yes NGO 0.96 
babycentre.co.uk UK No Yes No Yes Yes NGO 1.09 
beststart.org CAN Yes No No No No NGO -0.32 
cdc.gov USA No Yes No No Yes GOV -0.01 
commonhealth.wbur.org USA No Yes Yes Yes Yes NGO 0.07 
contemporaryobgyn.modern
medicine.com 
USA No No Yes No Yes NGO 0.12 
cuh.org.uk UK Yes No No No No GOV 0.01 
esht.nhs.uk UK Yes Yes Yes No No GOV -0.04 
fitpregnancy.com USA No No Yes No Yes NGO -0.08 
gloshospitals.nhs.uk UK Yes Yes No No No GOV -0.19 
gponline.com UK No No Yes No Yes NGO 0.26 
health.ny.gov USA No No No No Yes GOV -0.42 
health.qld.gov.au AUS Yes Yes No No No GOV 0.74 
health.ucsd.edu USA No Yes No No Yes COM -0.42 
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hqip.org.uk UK No No Yes No No NGO 0.34 
hse.ie IRE No No No No No GOV 0.35 
instituteofmidwifery.org USA No No Yes No No NGO -0.43 
ivfplus.com.au AUS No Yes No No No COM -0.67 
keepingyouwell.com USA No Yes No No Yes COM -0.79 
mainlinegi.com USA No Yes Yes No Yes COM 0.38 
marchofdimes.org USA No Yes No Yes Yes NGO 0.62 
markscrogginsmd.com USA No Yes No No No COM -0.67 
mayoclinic.org USA No Yes No No Yes COM 0.43 
netmums.com UK No Yes No Yes Yes NGO -0.20 
newkidscenter.com USA No Yes No No No NGO -0.39 
nhs.uk UK No Yes No Yes No GOV 0.70 
nichd.nih.gov USA No No No No Yes GOV -0.30 
noo.org.uk UK No No Yes No Yes GOV -0.10 
obesityaustralia.org AUS Yes Yes Yes No Yes NGO -0.08 
obfocus.com USA No Yes No No Yes COM -0.26 
parents.com USA No Yes Yes No Yes COM 0.33 
patient.info UK No Yes Yes Yes No NGO 0.04 
plus-size-pregnancy.org USA Yes Yes No No Yes NGO -1.68 
plymouthhospitals.nhs.uk UK Yes Yes No No No GOV -0.51 
pwhce.ca CAN No No Yes No No NGO -0.33 
qegateshead.nhs.uk UK Yes Yes Yes No No GOV -0.25 
raisingchildren.net.au AUS No Yes Yes Yes Yes NGO 0.80 
rcog.org.uk UK Yes Yes No No No NGO 0.96 
rdehospital.nhs.uk UK Yes Yes No No No GOV 0.03 
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royalberkshire.nhs.uk UK Yes Yes Yes No No GOV -0.19 
sahealth.sa.gov.au AUS Yes Yes No No No GOV -0.93 
seslhd.health.nsw.gov.au AUS No Yes No No No GOV 0.14 
stockport.nhs.uk UK Yes Yes No No No GOV 0.62 
tommys.org UK Yes No Yes No Yes NGO 0.37 
uhs.nhs.uk USA Yes Yes No No No GOV 0.24 
urmc.rochester.edu USA No Yes No No Yes NGO -0.69 
webmd.boots.com USA No No Yes No Yes COM 0.54 
webmd.com USA No No Yes No Yes COM -0.23 
whattoexpect.com USA No Yes Yes No Yes NGO 0.74 
womenandinfants.org USA No Yes No No Yes COM -1.02 




USA: United States of America 
UK: United Kingdom 




4.4.2 Quality of websites 
The median value for the overall credibility of websites was 5/9 (range 1-8), 7/12 for 
accuracy (range 2.5-11), 57.6/100 for readability (range 25-89.4) and 45/80 for content 
quality (range 20-62). The overall median technology quality value was 75/100 (range 40-
99). The value of the different technology assessment criteria included the following: 72/100 
for accessibility (range 41-97), 72/100 for user experience (range 33-92), 73/100 for 




There was higher credibility for the information on obesity-specific websites compared to 
general health ones (p=0.008) with no difference in other quality measures between the two 
groups. Websites targeting the general population had similar quality measures compared to 
those targeting healthcare users, except for lower readability score (p=0.001). The content 
quality was associated with the source of funding; NGO funded websites demonstrated better 
content quality compared to commercial and governmental websites (p=0.005). None of the 
remaining quality measures was affected by the source of funding (Table 4.4.2).  
 
Table (4.4.2): Summary of information and technology scores per websites group. Quality is 
summarised per median and range for each domain.  
 
 Credibility  Accuracy  Readability  Content quality  Technology  



































General focus 5.2 4-7 8 5-11 45 25-67 49 35-62 77 40-99 










0.87 Governmental 4.5 3-7 7 3-11 55 36-70 47 30-62 75 60-89 
NGO  5.5 1-8 8 3-11 59 25-72 49 20-62 76 40-85 
*Post-hoc analysis: 
Com vs Gov p= 0.003 
Gov vs NGO p=0.47  
Com vs NGO p=0.004 
 
The mean composite quality scores were not different among any of the websites groups. 
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NGO funded websites that are obesity-specific and targeting healthcare users demonstrated 
higher composite quality scores (β=0.410, p=0.048). Table (4.4.3) summarises the composite 
quality scores of compared groups.  
 
Table (4.4.3): Mean standardised composite quality scores and standard deviation per 
websites group. 
 
 Composite score P value 
 Mean SD  
Obesity 
specific 
-0.09 0.62 0.30 
General health 0.74 0.49 
Healthcare 
user focused 
0.0019 0.63 0.97 
General focus -0.003 0.31 
Commercial -0.22 0.53 0.206 
Governmental -0.0061 0.43 




4.5.1 Summary of findings 
The quality of information available online on obesity in pregnancy was quite varied. 
Countries with higher internet use in the healthcare sector, such as the UK and the USA, had 
a higher number of dedicated health websites. Interestingly there were more pregnancy 
dedicated websites funded by non-governmental sources compared to the other two groups. 
This, however, did not significantly affect the overall quality of health information provided. 
The distribution of the composite quality scores was relatively wide suggesting poor 
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adherence to available evidence-based guidelines on best practice to disseminate health 
information online.(26) 
 
Websites with limited funding (from individuals or small charities) demonstrated good 
information quality scores overall compared to the governmental ones that usually enjoy 
much larger funding and institutional support. The quality of used informatics technology 
was overall good in most included websites, probably due to an overall improvement in the 
available websites building tools.(105) 
 
Websites targeting pregnant women and other healthcare users employed much simpler and 
readable language compared to specialist websites. This could be attributed to the use of lay 
terms, avoiding jargon and complex medical language commonly used in websites dedicated 
to healthcare professionals. The content quality was significantly higher in the NGO funded 
websites. Overall, governmental health bodies did not invest enough efforts to develop 
reliable online health information that are amenable and relevant to the wider public.  
  
4.5.2 Limitations 
The results of this study are limited by the number of search engines used and the inclusion 
of websites in English language only. Our criteria to assess the information accuracy was 
driven by clinical importance with no input from lay users. Other health issues affecting 
pregnant women with obesity such as infertility and postpartum care might carry similar 
importance to lay health users. Quality assessment was conducted using non-validated criteria 
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with subjective assessment. While there was high correlation between the two assessors’ 
scores, there is a need to develop and validate assessment tools for health information quality.  
 
4.5.3 Implications for practice 
Modern healthcare systems need to adopt innovative, cheap and effective interventions to 
combat obesity on a wider scale. Sharing health information over the internet has a number of 
advantages including easy accessibility, low setup cost, unrestricted access and easy data 
storage with safe and interactive databases.(106) Online based systems can provide reliable 
and standardised health information to help improve the overall quality of shared care. This is 
particularly applicable to the postpartum period where the continuity of medical care is often 
lost and the chance for retaining added weight is higher.(107) 
Online healthcare information, in general, is still of mixed quality (26) and limited 
measurable applicability.(108) The guidelines published by the American Medical 
association are set to improve the quality of health information websites and standardise 
practice.(109) Their applicability, however, remains limited in current practice.(110)  
 
The quality of NGO funded websites specifically addressing obesity in pregnancy provided 
higher information quality; women should be encouraged to use them. Official healthcare 
bodies should invest more to improve the quality of governmental websites in order to stop 
the epidemic of obesity and improve public health in general. Involving multiple stakeholders 
including lay health users in the design and delivery of health information online can help to 
improve the overall quality. Our review has identified the top quality websites to help 





Online information on obesity in pregnancy is varied, more work is needed to standardise and 
improve the quality of reporting of online health information on this topic. Governmental 
bodies in particular need to invest more efforts to improve the quality of online health 
information on obesity in pregnancy.  
 
This chapter is based on the following publication: 
Al Wattar BH, Pidgeon C, Learner H, Zamora J, Thangaratinam S. Online health information 
on obesity in pregnancy: a systematic review. European Journal of Obstetrics & Gynecology 






CHAPTER 5  
USE OF DIETARY ASSESSMENT TOOLS IN 
RANDOMISED TRIALS EVALUATING DIET-





In this chapter, I have conducted a systematic review of the literature looking into the 
methods used to assess dietary intake in randomised trials on dietary intervention in 
pregnancy.   
 
5.1 Abstract 
Background Accurate assessment of participants’ dietary intake is a key element in 
interventional studies on lifestyle and dietary interventions. Dietary assessment in pregnancy 
is often complicated by the high inter-rater variability and the rapid change in dietary 
requirement. We performed a systematic review of the literature on commonly used dietary 
assessment tools in nutritional studies in a pregnant population.  
Methods We updated our previous search (until January 2012) using Medline and EMBASE 
up to December 2015 including all randomised trials on diet and lifestyle interventions in 
pregnancy. We screened and assessed relevant studies in duplicate by two independent 
reviewers. We assessed the characteristics of the dietary assessment tools, the timing, and 
frequency of use, and they were validated within the study population. We used the Chi-
squared test to check for any methodological factors associated with the relevant dietary 
assessment tools.   
Results In total 58 randomised trials met our inclusion criteria. Of these, only 67% (39/58, 
67%) employed some form of dietary assessment. The most commonly used assessment tool 
was a multiple days’ food diary (23/39, 59%), followed by a food frequency questionnaire 
(FFQ) (12/39, 31%) and a 24-hour recall (8/39, 20%). The majority of studies did not validate 
their assessment tools in their pregnant population (36/39, 92%) and none assessed their 
tools’ reliability. The use of dietary biomarkers was uncommon in pregnancy, reported only 
in one study. Only three studies (3/39, 8%) used pre-defined criteria to assess participants’ 
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adherence to the intervention. The rationale for using a particular tool was poorly reported. 
There was no association between the choice of dietary assessment tools and study quality 
(p= 0.10), study sample size (p= 0.19), year of publication (before or after 2005) (p=0.88), 
type of journal (general vs. specialist) (p = 0.33) or the journal impact factor (p=0.48). 
Conclusion Self-reporting dietary assessment tools are the most commonly used in 
nutritional studies in pregnancy. Evidence to support their applicability and validity in 
pregnancy is poor. More research is needed to develop and validate pregnancy specific 






Implementing diet and lifestyle interventions in pregnancy has the potential to improve 
maternal and fetal outcome such as gestational diabetes, pre-eclampsia and preterm birth in a 
high-risk population.(8,111)  
 
Assessing the participants’ habitual intake and their adherence to the dietary intervention is 
essential in interventional nutritional studies. Longitudinal dietary histories recording the 
subjects’ dietary intake prospectively, commonly used as the gold standard in a non-pregnant 
population, are expensive and labour intense tools.(112) Other forms of self-reporting tools 
such as food diaries and food frequency questionnaires can offer a suitable and user-friendly 
substitute.(113–115) 
 
Dietary assessment tools need be accurate, reliable, and valid for use within the study 
population to preserve internal validity.(112) Maintaining these characteristics in a pregnant 
population is often challenging due to the high inter-rater variability, (25) the common eating 
disorders, the rapid physiological changes, and the variation in energy requirements per 
trimester.(40)  
 
We undertook a systematic review to assess the characteristics and quality of the dietary 
assessment tools used in randomised trials on pregnant women, and the factors associated 
with their use.  
 
5.3 Methods 
5.3.1 Search strategy 
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We updated our previously published search for randomised studies on diet and lifestyle 
interventions in pregnancy (January 2012) using Medline and EMBASE until December 
2015 to identify any new studies. The search strategy was designed in a multistep process by 
combining search terms related to pregnancy and diet.(8) There were no language 
restrictions. The detailed search strategy is outlined in Appendix (9).  
 
5.3.2 Study selection 
We performed the study selection process in two stages. First, we screened the full titles and 
abstracts of all citations to identify potentially relevant studies. Then we assessed the full 
articles of shortlisted studies against our inclusion criteria. We included all randomised trials 
evaluating dietary interventions in pregnancy. We excluded non-randomised studies, those in 
animals and studies in a non-pregnant population. Any discrepancies were resolved by 
consensus among the reviewers.  
 
5.3.3 Quality assessment of included studies 
We assessed the quality of included randomised studies using the Jadad score.(116) One 
point was awarded for each of the following: study described as randomised, the 
randomisation method was appropriate; the study was described as double blinded, the 
allocation method was appropriate; the withdrawals and dropouts were described. Studies 
with a score above three were considered to be of high quality. A score of three was 
considered to be of moderate quality and studies with a score of two or less were considered 
to be of low quality.   
 
5.3.4 Data extraction and analysis 
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We extracted the data in duplicate using an electronic data extraction tool. We collected data 
on the study design, the country of the study, the characteristics of the randomised 
population, the study sample size, the type of the evaluated dietary interventions, the primary 
and secondary outcomes, and the journal’s impact factor. Journals with an impact factor of 
more than 10 were considered to be of high impact. We also reported on the type of the used 
dietary assessment tool, the time and the frequency of use within the trial, and if any 
evaluation of its validity and/or reliability was conducted.  
 
We reported frequencies and percentages for binary data using Microsoft Excel (2007) 
(Microsoft Corp., Redmond, WA, USA). We used logistic regression modelling to assess the 
effect of the reported study characteristics on the probability of using the relevant dietary 
assessment tool in the study population. Statistical analysis was conducted using SPSS (V20) 
(IBM Inc., New York, NY, USA).  
 
5.4 Results 
Electronic database search revealed 19,563 potentially relevant citations. Of these 58 
randomised trials met our inclusion criteria and were assessed in full. In total, we included 39 
studies (39/58, 67%) that employed a dietary assessment tool in our review reporting on 9728 




Figure (5.4.1): Identification and selection of studies that used dietary assessment tools to 


















5.4.1 Characteristics of included studies 
The largest number of studies was conducted in the USA (10/39, 27%), followed by Australia 
(6/39, 15%). The majority of included studies recruited women with any BMI (21/39, 54%) 
and only 5 targeted obese pregnant women with a BMI ≥30 (5/39, 13%). Thirteen studies 
focused on dietary interventions to reduce gestational diabetes with 10 studies recruiting 
women with positive diagnosis (10/39, 26%) and 3 recruiting women at high risk for 
gestational diabetes (3/39, 8%). Almost all of the included studies delivered the intervention 
Search results combined 
from databases:  
(n= 19,574) 
Full-text articles assessed 
for eligibility 
(n= 65) 
References excluded after 




Studies that did not meet 
the inclusion criteria and 
were excluded 
(n= 7) 
Non randomised trials (n=1) 
Duplicate publications of 
same trial (n=2) 
No life style intervention in 
pregnancy (n=4) 
Total number of Studies 
included  
(n= 58) 
Total number of studies 





by the end of the second trimester (35/39, 90%). The majority of evaluated dietary 
intervention were in the form of counselling and advice to pregnant women (30/39, 77%) and 
9 studies evaluated a combination of dietary and physical activity advice (9/39, 23%).  
 
Most studies were published in specialist medical journals and only 13% were published in 
general medical ones (5/39, 13%). Of these, only two were published in a journal with an 
impact factor> 10 (2/39, 5%). Table (5.4.1) provides a brief summary of the characteristics of 
the included studies. 
 
 
Table (5.4.1): Characteristics of randomised controlled trials on pregnant women using 






Journal Characteristics of 
intervention population 
BMI GA at 
intervention 








40, diagnosed with 
GDM at 24–28 week 
gestation. 
Any 24-28 weeks 
 
DASH diet was rich in 
fruits, vegetables, 
whole grains, low-fat 
dairy products, 
low in saturated fats 
and cholesterol, 
refined grains and 
sweets 
Weekly 3-day 
dietary records (2 















Nutritional education CASI (24-hour 
dietary recall +  
general nutrition 
questions) 







Age 18–50; GDM 
diagnosis, singleton 
pregnancy. 
<40 24-26 weeks Individually prescribed 









neuroleptic drugs, and 
vegetarianism or 
veganism 












with no pre-existing 
health conditions or 
diet 
Any <24 weeks In home, prenatal 
nutritional advice 














Diet, Exercise and 
Breastfeeding 
Intervention (DEBI) 
for women with 
gestational diabetes 
7 days dietary fat 
intake diary 







Age 18–45, diagnosed 
with GDM or IGT, no 
chronic illness 
affecting carbohydrate 
metabolism; No type 
1 or type 2 diabetes; 
not using insulin prior 
to providing consent 
Any <34 weeks dietary counselling on 
non-starchy food 









age 18-45, diagnosed 
with GDM. 
Any 28 weeks Patients introduced to 
diabetes food guide 
and current Canadian 
dietary 
recommendations. 
3 days diary + FFQ 
Guelinckx 






Obese white pregnant 
women < 15 weeks 
gestation 
>29 15 weeks Nutritional advice 
from a brochure +/- 
lifestyle education by a 
nutritionist 










Age 18-43. <15 
weeks gestation, 







15 weeks Fish oil supplement + 
vitamin E daily during 
pregnancy and 
lactation. + detailed 
nutritional counselling 
from trained research 
assistants. 
7 days food diary 
Hawkins 




age18–40, no history 
of Type 2 diabetes, 
hypertension, heart 
disease or chronic 




planning to continue 
the pregnancy to term. 
≥ 25 < 18 weeks In-person behavioural 
counselling sessions 
and 30 minutes of 
moderate-intensity 
activity per week 
24 hour recalls 










women (<26 weeks 
gestation) 
Any 26 weeks Community-based 
group exercise 
sessions + home 
exercise and dietary 
counselling 





Pregnant women less 
than 17 weeks 
gestation and no 
metabolic diseases 
Any <17 weeks Dietary counselling 
with probiotics or 
placebo 








English speaking, ≥18 
years, <26 weeks 
gestation 
Any 26 weeks Teaching and 
counselling session 
about nutrition, 
exercise and weight 
gain using the (Video 
Doctor) 






English speaking, ≤14 
weeks gestation, age 
18-45 years 
Any 14 weeks Nutritional advice Eating habit 
questionnaire (used 
to distract from 







Pregnant women at 
risk of GDM < 19+6 
weeks. Singleton 
pregnancy, age < 18 
years. 
>29 <19 weeks 
+ 6 days 
Five Individual 
sessions and 4 optional 
telephone calls with a 
lifestyle coach. Daily 
intake of Vitamin D. 
3 days food diary +  













ethnicity, age 21-38 
19-32 17-18 weeks Nutritional advice, low 
Cholesterol diet and 
supplement intake in 
pregnancy 
7 days weighed 
dietary diary 
Kiefferv 






women, age < 18 
years, resident in 
southwest Detroit 
residents, <20 weeks 
gestation. 
Any <20 weeks Healthy Mothers on 
the Move dietary 
programme 
implemented in 2 
home visits and 9 










Pregnant women at 
high risk of 
gestational diabetes 
Any 12 weeks Dietary and lifestyle 
advice 






women, 8-12 weeks 
gestation, at least one 
risk factor for GDM 
Any 8-12 weeks Individual intensified 
counselling on 
physical activity, diet, 
and weight gain 
FFQ (181 items) 
Man Shek 




Chinese, residents in 
Hong Kong, age≥18, 
diagnosed with IGT 
but otherwise in 
general good health, 
understand Chinese 
language. 




counselling by a 
registered dietician 






Age 18-45, singleton 
pregnancy, diagnosis 
of GDM <35 weeks. 
Any <35 weeks Individualised dietary 
advice 





Age 18-45, singleton 
pregnancy, no 
previous GDM, non-
smoker, diagnosis of 
GDM 
Any 28-32 weeks Individualised dietary 
advice 






<20 weeks gestation, 
singleton pregnancy, 
age >18, ability to 
read and understand 
English 
Any 20 weeks Detailed dietary 
education tailored for 
the assigned diet 








<20 weeks gestation, 
singleton pregnancy, 
18 years or older, read 
and understand 
English 
Any <20 weeks Detailed dietary 
education tailored for 




3 days food diary 
Petrella et 
al 2013 





Age >18 years, 
singleton pregnancy 
≥25 12 weeks Therapeutic Lifestyle 
Changes (TLC) 
Program 







Age >18 years, 
singleton pregnancy, 
gestation <20 weeks 
≥19.8 20 weeks Education about 
weight gain, healthy 
eating, and exercise. 











≥30 15-18 weeks One-to-one and group 
sessions with health 
trainer providing 
dietary and physical 
activity advice 
24 hour recalls + 
short FFQ 
Quinlivan 






pregnancies, obese or 
overweight, English 
speaking 




























Nutritional advice on a 
moderately energy 
restricted diabetic diet. 
3 days food diary 






Age >18 years, 
singleton pregnancy, 




≥18.5 18 weeks Advice on healthy 
lifestyle, diet and 
physical activity with 
individualised goals 







BMI 25-45, age ≥25, 
singleton pregnancy. 
25-45 13-28 weeks Nutritional education, 
dietary counselling and 
food provision 
24-hour recalls 






History of GDM/ 
BMI ≥ 30, < 20 weeks 
≥30 20 weeks lifestyle counselling 
encouraging healthy 
diet and physical 
activity 







>18 years old, <20 
weeks gestation, 
fluent in Norwegian 
or English 




hands-on cooking class 





82 items FFQ + 24 
hour recalls 
Thornton 
et al 2009 







women with singleton 
pregnancy. 
≥30 12-18 weeks Advised on a balanced 
nutritional regimen. 





USA Obesity Age >18, > 8 weeks 
gestation (at first 
antenatal booking). 














of >4kg, aged ≤18 
Any <18 weeks Nutritional advice 
following a low 
glycaemic index diet 
3 days food diary 
Wang et 
al 2015 
China Asia Pac J 
Clin Nutr 
Diagnosed with 
GDM, age 22-38, no 
pregnancy-related 
complications, no 
history of diabetes, 
hypertension or 
GDM. 
Any 24-28 weeks Individualised dietary 
guidance 










≥30 15 weeks Nutritional advice and 
provision of 
supplements 
7 days weighed 
food diary 
 
GDM: Gestational diabetes mellitus 
IGT: intolerance glucose test 
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FFQ: Food frequency questionnaire 
 
5.4.2 Quality assessment of studies using dietary assessment tools 
The randomisation method was appropriate in two-thirds of the studies (28/39, 72%) and only 
three were blinded (3/39, 8%). Allocation concealment was adequate in only two studies 
(2/39, 5%). More than 80% of the included studies described the withdrawals and loss to 
follow-up appropriately (32/39, 82%) (Figure 5.4.2).  
 
 



















Reported loss to follow up and withdrawls
Appropriate blinding
Described as a blinded study
Appropriate randomisation
Described as a randomised study
Yes No Not reported
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5.4.3 Characteristics of dietary assessment tools 
The most commonly used tool to assess dietary intake in pregnancy was short-term food 
diaries (23/39, 59%), followed by food frequency questionnaires (FFQ) (12/39, 31%) and 24-
hour recalls (8/39, 20%). Four studies used two assessment tools jointly.(117–120) There was 
a large variation in the use of short-term food diaries. Three days diaries were the most 
commonly used (13/23, 57%), followed by 7 days diaries (8/23, 35%). The use of weighted 
food diaries was only reported in two studies.(117,121) 
 
Most studies that used a FFQ adopted or modified a previously validated version in a similar 
or different study population (6/39, 15%). Assessed FFQs ranged in the number of included 
items between 13 and 181.(122–128)  
Two studies developed and validated the FFQ in the study population using non-weighted 5 
days food diaries (2/39, 5%) (129) and 24 hour recalls.(120) Only one study validated the 
content of the 24-hour recall via a panel of experts.(130) A predefined adherence criteria to 
the dietary intervention was only provided in four trials (4/39, 10%).(129,131–133) Dietary 
biomarkers were used to assess the effectiveness of the intervention in three studies only 
(3/39, 8%) (117,121,125) and to assess participants’ adherence to the intervention and change 
in dietary intake in one trial only.(128) (Table 4.4.1)     
 
5.4.4 Factors associated with use of dietary assessment tools 
Logistic regression modelling revealed no relationship between the decision to use dietary 
assessment tools and the study quality (β= 1.183, p= 0.10), year of publication (before or 
after 2005) (β= -0.997, p=0.36), journal impact factor (β= -0.063, p=0.195), type of journal 





Our review summarises the use and quality of dietary assessment tools in randomised trials 
on dietary interventions in a pregnant population. Less than two-thirds of interventional 
studies included a dietary measurement process. This practice did not seem to correlate with 
methodological choices such as the study quality or the sample size. Self-reporting tools were 
the most commonly used, which is consistent with common practice outside pregnancy.(134)  
 
5.5.1 Limitations 
The majority of included studies did not provide detailed information on the rationale for 
choosing their preferred dietary tools which limited evidence synthesis on best practice. Only 
a handful of studies validated their assessment tools in the study population. This limited our 
ability to describe the best validation methods for dietary tools in pregnancy.   
 
5.5.2 Dietary tools in pregnancy 
The use of self-reporting dietary tools is common in pregnancy. These, however, commonly 
result in over or under-estimation of intake data. Food diaries are more likely to under-
estimate certain nutrients in female and obese participants.(135) The lack of standardised 
portion sizes and measurement tools also increases variability.(136) Using multiple days 
diaries over a long period of time can increase dropouts (137) and bias habitual intake.(138) 
 
The use of FFQs in pregnancy was also popular. FFQs’ sensitivity to capture dietary changes 
in trial settings is generally trivial (139), and can be affected by a number of factors such as 
the number of items in the FFQ, the population literacy, the study sample size, and the type of 
the dietary intervention introduced.(40) FFQs’ reliability in pregnancy is further undermined 
due to the instability of dietary intake between trimesters and common eating disorders such 
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as hyperemesis. Adopting a previously validated FFQ in a similar population is a common 
practice in nutritional trials.(140) However, the high inter-rater variability in pregnancy can 
increase the random error in FFQs and undermine their accuracy.(135)  
 
24-hour recalls can capture day to day variability in dietary intake with reasonable sensitivity 
in trial settings.(136) The quality of the recalls can be improved by testing their content and 
face validity(23), using the multi-pass method (120) and by combining them with other 
assessment methods such as a FFQ.(118) A number of factors can affect their validity in 
pregnancy such as poor participant’s attention, memory gaps, and variation in estimating 
portion sizes.(135)  
 
5.5.3 Implication for future research 
Pregnancy increases the systematic and random reporting errors in the dietary assessment 
process. A number of methods can be employed to improve the quality of dietary assessment 
in pregnancy. Validating and combining dietary assessment tools can help to reduce the 
reporting bias.(141) Accommodating for basic metabolic rate and expected energy intake in 
the study population is also helpful to reduce bias.(142) The use of biomarkers to assess 
specific nutrients’ intake can offer a more accurate assessment.(78) With many biomarkers 
now available, it is possible to objectively assess the intake of many nutrients of interest 
using urine or blood samples.(66) Added cost, workload and invasive testing are potential 
drawbacks.(66) Furthermore, the changing physiology in pregnancy might affect the accuracy 
of some biomarkers. The applicability of biomarkers in pregnancy is still limited by the gap 
of knowledge on their validity, reliability, and reproducibility.(143) Employing new 
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technological methods such as mobile and internet-based assessment tools can also help to 
reduce measurement error.(144) 
 
5.6 Conclusion 
Self-reporting dietary assessment tools are commonly used in interventional dietary trials in 
pregnancy. The quality and applicability of existing tools are low with poor consideration for 
the characteristics of a pregnant population. 
 
 
This chapter led to the following publication: 
 Al Wattar BH, Mylrea-Lowndes B, Morgan C, Moore AP, Thangaratinam S. Use of dietary 
assessment tools in randomized trials evaluating diet-based interventions in pregnancy: a 









CHAPTER 6  
 
VALIDATION OF SEMI QUANTITATIVE FOOD 





In this chapter, I conducted a primary validation study of a custom designed food frequency 
questionnaire and a short dietary questionnaire within the ESTEEM trial pregnant population.  
 
6.1 Abstract 
Background Pregnancy poses many limitations on the assessment of dietary intake in 
nutritional studies. We validated a food frequency questionnaire (FFQ) and a short 12 items 
questionnaire (ESTEEMQ) against 24 hours dietary recalls to assess the dietary intake in a 
randomised, high-risk, multi-ethnic British pregnant population.   
Methods We assessed the dietary intake of pregnant women who met the inclusion criteria 
for the ESTEEM trial before delivering the intervention in the second pregnancy trimester. 
We used three 24 hour dietary recalls as the reference method. We adapted our FFQ and 
ESTEEMQ from previously validated versions in dietary studies on the Mediterranean diet. 
We tested the agreement between the FFQ and the 24 hour recalls for mean values of food 
groups, energy, and micronutrients using intraclass correlation coefficients, Kappa statistics, 
and the Bland & Altman method. We identified the intake quintiles and reported the degree 
of gross misclassification and complete or adjacent agreement. Similarly, we assessed the 
agreement between the ESTEEMQ and the FFQ to assess participants’ adherence to the 
intervention.  
Results Sixty-five participants were included. Half were Asians (33/65, 50.7%) and 66% had 
a BMI ≥30 Kg/m2 (43/65, 66.4%). The agreement between the FFQ and the 24-hour recalls 
was good for key foods in the Mediterranean diet such as meat (ICC 0.56) and fish (ICC 
0.52). Other important food groups such as bread (ICC 0.46), legumes (ICC 0.25), and 
pastries, cakes & sweets (ICC 0.21) demonstrated moderate agreement. The ICC agreement 
for olive oil and nuts intake was poor with moderate quintile cross-classification. The 
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agreement between the ESTEEM Q and the FFQ was moderate to good for 8 out of 12 
questions with moderate index score correlation. The majority of participants suffered from 
pregnancy-related gastro-intestinal disorders such as nausea and vomiting (82%). 
Conclusion Our modified FFQ and ESTEEM Q are useful tools to assess adherence to a 







Nutritional studies aim to evaluate the effect of dietary and lifestyle interventions on health 
outcomes and associated disease such as diabetes and cardiovascular events.(145) Accurate 
assessment of baseline nutrients intake, adherence to the intervention and changes in habitual 
dietary intake are integral components in randomised nutritional studies.(38)  
 
In pregnancy, randomised studies often use self-reporting dietary assessment tools to record 
food intake and dietary habits.(81) However, the high inter-rater variability and rapid changes 
in dietary requirements specific to pregnancy pose many limitations on the validity of these 
tools.(40) Their validity can be further undermined by contributing factors such as the low 
population literacy, the iteration associated with frequent use, and the reduced sensitivity 
when assessing complex dietary interventions. Assessing the validity, reliability, and 
accuracy of the chosen dietary assessment tool within the study population is therefore 
warranted.(40)  
  
We undertook a randomised trial (ESTEEM) to evaluate the effect of a Mediterranean-based 
dietary intervention on pregnancy outcomes in a multi-ethnic British population.(146) Our 
objective was to validate a purposely developed food frequency questionnaire (FFQ) to assess 
the dietary intake of the ESTEEM population. We also evaluated the performance of a 






6.3.1 Study design 
We conducted a prospective validation study within a randomised trial on the effect of 
Mediterranean diet on maternal and fetal outcomes (ESTEEM). The recruitment and 
randomisation criteria for ESTEEM is highlighted in figure (2.4.1).  
Participants of the validation study were recruited consecutively by the ESTEEM trial 
dietician from both arms of the study at their first appointment (<18 weeks gestation). 
Following consent, participants were asked to complete all dietary assessment questionnaires 
before delivering the dietary intervention.   
 
6.3.2 Dietary assessment   
We used a series of three consecutive 24-hour dietary recalls as the reference method to test 
the validity of the FFQ. Participants were also asked to complete the ESTEEM Questionnaire 
to assess its validity against the FFQ.  
 
6.3.2.1 24-hour dietary recalls 
During the first face to face meeting, each participant completed two 24 hour recalls covering 
the intake of the last 48 hours. The following day the ESTEEM dietician collected a third 
recall over the phone before starting the intervention. We used a generic 24-hour recall 
proforma to collect data coupled with the multi-pass method to improve recall.(76) We aimed 
to capture two weekdays and one weekend day recalls where possible. Household 
measurements were used to estimate portion sizes. We estimated the daily intake for each 




6.3.2.2 Semi-quantified FFQ 
We adapted the ESTEEM FFQ from a previously validated version used for dietary 
assessment in a Mediterranean pregnant population in Spain (INfancia y Medio Ambiente 
(INMA)).(147) We added specific items to capture locally consumed food items specific to 
our population such as Asian and Afro-Caribbean food.(148–150) The FFQ included 111 
questions, each with nine possible responses for consumption frequency ranging from ‘never 
or less than once per month’ to ‘six or more per day’. We added 11 multiple choices 
questions to assess eating habits specific to a Mediterranean diet and common pregnancy 
eating disorders that could affect dietary intake such as nausea and vomiting. Portion sizes 
were standardised using The Food Standards Agency UK portion sizes.(151) We piloted the 
FFQ amongst the ESTEEM trial service user team to test its face and content validity which 
were judged to be high. We asked the ESTEEM team to evaluate the developed FFQ at 
different stages against established and validated questionnaires during dedicated 
consultation meetings.  
 
6.3.2.3 ESTEEM Questionnaire (ESTEEM Q) 
The ESTEEM Q was based on a previously validated version in a Mediterranean non-
pregnant population.(77) We modified it to include 10 questions on the consumption of key 
food items in the Mediterranean diet and 2 questions on dietary preference for white meat and 
extra virgin olive oil. Two questions were omitted compared to the original version, one 
concerning alcohol intake (not applicable in pregnancy); and one concerning the intake of a 
Spanish sauce (Sofrito) which is not commonly consumed in a British population. A score of 
0 or 1 was given for each question against a pre-specified cut-off value. The reference values 
were adopted from a previously validated adherence criteria for the Mediterranean diet.(152) 
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The sum of these scores generated an index score of each participant’s adherence to the 
intervention (range 0-12). We added 7 dichotomous questions to screen for common 
pregnancy eating disorders that could affect dietary intake e.g. nausea and vomiting.  
 
6.3.3 Data collection    
We recorded the data in each participant’s trial written case record files and later entered 
them into the ESTEEM secure internet database anonymously. We generated mean nutrients 
and food intake values from the FFQ using the method described in the development of the 
EPIC FFQ.(153) We calculated the daily average nutrient intake for each participant by 
multiplying the frequency of consuming each nutrient by its composition within the specified 
portion size.(153) We obtained nutrient values from The McCance & Widdowson’s 
Composition of foods Integrated dataset.(154) 
We used the same method to calculate the nutrient values from the ESTEEM Q scores using 
matching questions in the FFQ for each food item. We used Dietplan v06 (Forestfield 
Software Ltd, Horsham, United Kingdom) to calculate mean nutrients and food intake values 
from the completed 24-hour dietary recalls.  
 
6.3.4 Statistical analysis 
We estimated a sample size of 65 to be sufficient to validate the tools within the study 
population based on previous literature.(140) We assessed nutrients data for completeness 
and excluded cases with >20% of missing data entries in the FFQ and the ESTEEM Q. We 
excluded cases reporting unrealistic high total energy intake on the FFQ for women in the 
second trimester of pregnancy (>95th centile).  We performed normality testing and assessed 
the type of data distribution (Type A or B) when non-normal distribution was detected. We 
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applied the relevant log transformation method to the type of data using established models 
such as the Box-Cox (53) and added a small constant to avoid taking the log of zero. We 
calculated the “density” of intake (intake divided by the total energy intake) as a way of 
adjusting for total energy intake as well as analysing absolute food and nutrients intake 
values. 
 
We tested the agreement between the mean intake values of food groups, energy, and 
micronutrients from the FFQ and the 24-hour recalls using intraclass correlation coefficients. 
We used the Bland & Altman (155) method to graphically check the agreement between the 
two tools by plotting of the differences of the measurements against their means. We used 
paired t-tests to investigate evidence of consistent disagreement. We identified the intake 
quintiles for each variable from the 24-hour food recall data and reported the degree of gross 
misclassification (the proportion classified into opposite quintiles) and complete or adjacent 
agreement (the proportion classified into the same or an adjacent quintile) compared to the 
FFQ as additional indices of validity. 
 
We used Kappa statistics to determine the agreement between the ESTEEM Q questions and 
their matched values derived from the FFQ. We used paired t-tests to investigate evidence of 
consistent disagreement in the dataset. We calculated the Pearson product moment 
correlations to test the association between the mean ESTEEM Q index score and that 
derived from the FFQ. 
 
We considered the agreement between nutrient values using ICC to be good for a score above 
0.5, acceptable for 0.49-0.2 and poor if <0.2.(156) 
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For Kappa statistics, good agreement was judged as values above 0.6, acceptable agreement 
for values between 0.6 and 0.2, and poor agreement for values below 0.2.(156) 
We judged the Quintile cross-classification of the agreement between the two tools as good if 
≥ 50% were in the same quartile and ≤ 10% were in opposite quintiles. The agreement was 
judged as poor if <50% were in the same quartile and >10% in in opposite quintiles. Values in 
between these ranges were judged as moderate agreement.(156)  
 
6.4 Results 
6.4.1 Characteristics of participants 
In total, 65 participants completed the dietary assessment tools. We excluded 15 women from 
the FFQ validation against the 24h recalls (4 cases due to incomplete FFQ data, and 11 for 
over reporting of the total energy intake) (Figure 6.4.1). 
 
Figure (6.4.1): Flow chart of the ESTEEM validation study  
 
 
  Participants recruited from the ESTEEM trial 
n=65  
Questionnaires administered 
FFQ n= 65 
ESTEEM Q n= 65 
24 hour recalls n= 65 
   
Questionnaires analysed 
FFQ n= 43 
ESTEEM Q n= 50 
24 hour recalls n= 43 
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The mean participants’ age was 31.57 (SD 5.14). The median gravidity was 2 (range 1-9) and 
median parity was 1 (range 0-5). Half the participants were Asian (33/65, 50.7%), a third 
were White (17/65, 26.1%) and 18% were Black (12/65, 18.4%). More than half had a BMI 
≥30 Kg/m2 (43/65, 66.4%). Table (6.4.1) provides a summary of the participants’ baseline 
characteristics. 
 










6.4.2 FFQ vs 24 hour recalls 
Overall, food groups mean values demonstrated moderate agreement with those of the 24 
hour recalls (Table 6.4.2).  
The agreement was good for key foods in the Mediterranean diet such as meat (ICC 0.56) and 
fish (ICC 0.52). Other important food groups such as bread (ICC 0.46), vegetables (ICC 
0.20), legumes (ICC 0.25), eggs (ICC 0.23) and pastries, cakes & sweets (ICC 0.21) 
demonstrated acceptable agreement. The agreement for olive oil and nuts intake was poor 
with moderate quintile cross-classification agreement. Majority of food groups demonstrated 
good quintile cross-classification agreement except eggs, legumes, olive oil and nuts.  
Mean age 31.57 (SD 5.14) 
Median parity 1 (range 0-5) 
Median gravidity   2 (range 1-9) 
Ethnicity  
 White 17/65 (26%) 
 Asian 33/65 (51%) 
 Black 12/65 (18%) 
 Other 3/65   (5%) 
  
Body mass index (Kg/m2)  
 Normal (≤24.9) 11/65 (17%) 
 Overweight (25-29.9) 11/65 (17%) 







Table (6.4.2): Summary of mean values of food groups between FFQ and 24 hour recalls. 
 












194.7 (144.7) 94.0 (66.2) 0.31 0.008 0 66 
Eggs 25.1 (26.4) 18.3 (26.9) 0.23 0.064 0 37.5 
Meat 95.0 (73.9) 95.7 (68.7) 0.56 0.026 0 64 
Fish 85.0 (90.0) 40.9 (58.1) 0.52 <0.001 2 44 
Fruits 345.5 (233.0) 152.5 (125.3) 0.11 <0.001 8 64 
Fruit juice 71.6 (96.8) 37.0 (73.0) 0.23 <0.001 12 28 
Vegetables 323.1 (192.0) 118.8 (85.9) 0.20 <0.001 8 60 
Potatoes 97.5 (62.3) 47.0 (50.9) 0.05 <0.001 12 60 
Bread 70.3 (63.7) 83.4 (76.0) 0.46 0.008 2 54 
Legumes 30.7 (34.1) 19.8 (27.0) 0.25 0.22 8 32 
Nuts 4.7 (9.2) 2.6 (7.6) 0.14 0.007 84 16 










The agreement for most macronutrients was moderate (protein ICC 0.46, carbohydrate ICC 
0.45, Non-starch polysaccharides ICC 0.40, fat ICC 0.36, fatty acids ICC 0.25). Unsaturated 
fatty acids (PUFA, MUFA, Linoleic acid, and Marine n3 Fatty Acid) showed poor agreement 
with moderate quintile cross-classification agreement (Table 6.4.3). Cross-classification 
agreement for most remaining micronutrients was good to moderate. Appendix (9) illustrates 
the Bland-Altman graphs for both food groups and nutrients between the FFQ and the 24-
hour recalls.   
 
 











Protein (g) 88.4 (35.7) 61.3 (18) 0.46 0.30 6 66 
Carbohydrate (g) 261.8 (96.5) 191 (72) 0.45 0.01 2 66 
Sugars (g) 111.3 (45.7) 61.6 (28.5) 0.09 0.00 4 60 
NSP (g) 201 (7.3) 14.6 (7.3) 0.40 0.80 4 64 
Fat 96.0 (34.4) 60.1 (18.1) 0.36 0.001 2 66 
Fatty Acids 31.5 (11.7) 20.0 (8.0) 0.25 0.022 2 56 
MUFA 38.7 (13.6) 18.9 (6.7) 0.00 <0.001 16 42 
PUFA 23.8 (10.0) 11.2 (5.6) 0.00 <0.001 8 48 
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Linoleic acid (g) 12.1 (5.7) 4.9 (3.9) 0.00 <0.001 16 48 
Marine n3 Fatty 
Acid (g) 
4.1 (3.0) 0.02 (0.03) 0.00 <0.001 32 40 
Cholesterol (mg) 319.9 (184.9) 181.7 (112.2) 0.60 0.014 2 72 




0.18 0.064 2 60 
Potassium (mg) 3707.4 
(1143.3) 
2265.2 (784.5) 0.18 <0.001 6 54 
Calcium (mg) 971.4 (364.8) 567.9 (215.0) 0.41 <0.001 6 70 
Magnesium (mg) 345.4 (111.7) 213.7 (90.3) 0.26 <0.001 6 58 
Phosphorous 
(mg) 
1476.6 (540.3) 1012.3 (306.3) 0.40 0.91 0 62 
Iron (mg) 15.6 (5.3) 9.10 (4.4) 0.14 <0.001 8 52 
Copper (mg) 1.6 (0.6) 1.1 (0.7) 0.05 0.31 4 62 
Zinc (mg) 24.7 (20.5) 6.6 (2.8) 0.00 <0.001 10 42 




0.07 0.001 4 54 
Manganese (mg) 4.6 (1.8) 2.8 (2.0) 0.20 <0.001 2 66 
Iodine (µg) 265.3 (169.2) 80.1 (37.3) 0.00 <0.001 12 42 
Selenium (µg) 77.2 (44.8) 36.2 (14.8) 0.13 <0.001 6 56 
Retinol (µg) 479.9 (983.5) 180.8 (120.4) 0.14 0.001 2 64 
Carotene (µg) 625.7 (251.3) 2179.3 
(2256.5) 
0.00 <0.001 20 40 
Vitamin D (µg) 7.1 (6.9) 1.8 (1.9) 0.20 <0.001 6 58 
Vitamin E (mg) 17.6 (7.8) 6.7 (3.5) 0.00 <0.001 16 42 
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Thiamine (mg) 1.6 (0.5) 1.2 (0.6) 0.29 0.51 0 68 
Riboflavin (mg) 1.8 (1.1) 1.0 (0.4) 0.03 0.001 8 60 
Niacin (mg) 25.1 (15.2) 16.8 (6.7) 0.11 0.88 2 56 
Vitamin B6 (mg) 2.6 (1.3) 1.6 (0.6) 0.00 0.10 4 58 
Vitamin B12 
(µg) 
9.9 (9.3) 3.0 (2.3) 0.31 <0.001 8 64 
Folate (µg) 316.8 (113.0) 190.7 (94.4) 0.29 0.002 4 68 
Pantothenate 
(mg) 
7.1 (2.9) 3.5 (1.2) 0.00 <0.001 10 50 
Biotin (µg) 38.1 (14.9) 21.5 (13.9) 0.25 <0.001 2 56 
Vitamin C (mg) 163.8 (74.5) 95.6 (77.8) 0.21 <0.001 0 56 
 
 
6.4.3 ESTEEM Q vs FFQ 
Eight out of the 12 questions in the ESTEEM Q demonstrated moderate to good agreement 
with the FFQ (Olive oil use κ 0.52, fruits κ 0.36, butter/margarine κ 0.33, sugary drinks κ 
0.50, fish κ 0.30, commercial sweets κ 0.35 and nuts κ 0.36) (Table 6.4.4). Agreement for 
estimating the quantity of olive oil consumed (κ 0.00) and pulses intake (κ 0.15) was poor 
between the two tools. There was poor correlation and agreement between the ESTEEM Q 
total index score and that derived from the FFQ (Pearson 0.24, ICC 0.24 (95% CI 0.00 - 





Table (6.4.4): Summary of mean values of food groups and index score between Esteem Q 
and the FFQ. 
 
A: Food groups 










Do you use olive oil as the main fat to cook with? (Y/N) 
 
Yes 77.6 53.6 0.52 0.14 0.00 
How many tablespoons do you consume of olive oil in a 
given day (including oil used for frying, salads, meals eaten 
away from home, etc.)? 
 
≥4 Tbsp5 91.5 91.5 0.00 - - 
How many servings of vegetable do you consume per day? 
(1 serving = 200 g or palm size [consider side dishes as half 
a serving]) 
 
≥2 48 57.3 0.22 0.13 0.95 
How many fruit units (including natural fruit juices) do you 
consume per day (1 unit = 1 piece of fruit, or equivalent (10 
grapes, slice of melon) or small glass of juice)? 
 
≥3 68 50 0.36 0.14 0.00 
How many servings of red meat (lamb, beef, goat, pork), 
processed meat (sausages, hamburgers) or red meat 
products (bacon, ham) do you consume per day? (1 serving: 
100–150 g or small palm-sized portion) 
 
<1 85.7 82.3 0.20 0.13 0.07 
How many servings of butter, margarine, or cream do you 
consume per day? (1 serving: One teaspoon) 
 
<1 77.6 66.3 0.30 0.14 0.01 
How many drinks containing sugar do you consume per 
day? (e.g. tea or coffee, canned fizzy drinks or sweetened 
fruit squash) 
 
<1 76 51.7 0.50 0.14 0.00 
How many servings of pulses (e.g. lentils, beans, dahl) do you 
consume per week? (1 serving : 150 g, fist size) 
≥3 69.4 63.8 0.15 0.11 0.08 
How many servings of fish or shellfish (white fish, oily fish 
e.g. salmon, or shellfish like mussels) do you consume per 
week? (1 serving 100–150 g of fish or 4–5 units or 200 g of 
shellfish, a palm-sized portion) 
≥3 66 51.1 0.30 0.12 0.00 
How many times per week do you consume commercial 
sweets or pastries (not homemade), such as cakes, cookies, 
biscuits, or custard? 
 
<2 69.4 52.8 0.35 0.14 0.00 
 ≥3 79.1 67.4 0.36 0.11 0.00 
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How many servings of nuts (including peanuts) do you 
consume per week? (1 serving 30 g, small handful) 
 
 
Do you preferentially consume chicken or turkey instead of 
veal, pork, hamburger, or sausage? 
 
Yes 65 50 0.30 0.15 0.03 
 
 










ICC P value 
EQ Total Score 5.4  4.8 - 5.9 
0.24 0.24 (95% CI 0.00 - 0.55) 0.07 





6.4.4 Dietary habits 
The majority of participants included in the study suffered from nausea and vomiting in the 
first part of their pregnancy (41/50, 82%). About half of them reported that this has affected 
their usual dietary intake (27/50, 54%). Half the participants reported other eating disorders 
common in pregnancy such as fullness of stomach (32/50, 64%), indigestion (27/50, 54%) 














FFQ (N=50)    
Nausea or vomiting during your pregnancy 41 (82%) 8 (16%) 1 (2%) 
Symptoms affecting food intake in the last 4 months 27 (54%) 20 (40%) 3 (6%) 
    
ESTEEM Q (N=50)    
Fullness of Stomach 32 (64%) 17 (34%) 1 (2%) 
Bloatedness 22 (44%) 27 (54%) 1 (2%) 
Vomiting 14 (28%) 35 (70%) 1 (2%) 
Nausea 19 (38%) 30 (60%) 1 (2%) 
Indigestion 27 (54%) 22 (44%) 1 (2%) 
Constipation 25 (50%) 23 (46%) 2 (4%) 




6.5.1 Summary of main findings 
Overall, our FFQ demonstrated a moderate performance for a number of key food items 
relevant to Mediterranean diet such as fish intake. There was good to moderate quintile cross-
classification agreement allocation for key micronutrients such as PUFA and MUFA. 
However, the FFQ had low accuracy for capturing the intake of less commonly consumed 
food items such as nuts and olive oil, as well as most micronutrients. This could be attributed 
to the large variation in food intake at the beginning of the pregnancy leading to reduced FFQ 
accuracy 
Compared to the FFQ, the ESTEEM Q performed well for most key food groups in a 
Mediterranean diet with a reasonable overall index score agreement. Some of the key items 
such as red meat and vegetables were poorly captured by the ESTEEM Q compared to the 
FFQ. This could be attributed to the multiple questions allocated for each food group in the 
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FFQ potentially serving as a memory aid. A large number of our participants suffered from 
pregnancy-related eating disorders when completing the questionnaire which contributes to 
higher inter-rater variability and lower dietary assessment accuracy.(40)  
 
6.5.2 Strength and limitations 
To our knowledge, this study is the first to design and test the validity of a food frequency 
questionnaire in a British multi-ethnic population with a focus on Mediterranean diet. We 
assessed the dietary intake at a neutral phase before introducing the ESTEEM intervention to 
reduce bias. We used a sound methodology for validating dietary assessment tools and 
adjusted it for pregnancy settings.   
 
We amended our questionnaires to accommodate for local food culture and increase 
sensitivity. We designed our FFQ to be user-friendly by reducing the number of questions 
compared to previous versions and standardising the portion sizes. We aimed to reduce 
systematic bias in the 24 hour recalls by including multiple measurements of weekdays and 
weekends, using the multi-pass method, and by using a food picture atlas to help standardise 
portion sizes.(157,158) We reported on common pregnancy eating disorders in our 
population as potential confounders which are rarely assessed in similar studies.(159)   
 
Our findings are limited by the over-reporting of energy and certain food items in the FFQs. 
This may be due to misunderstanding the FFQ questions and memory gaps.(160) We 
addressed this by excluding overtly skewed cases from the analysis. The study’s time frame 
was relatively short which may have reduced the accuracy for assessing the intake of less 
commonly consumed food items. Our sample size was relatively small and restricted to 




6.5.2 Implication for research 
To date, there is a limited number of food frequency questionnaires that are validated for use 
in a multi-ethnic pregnant population.(161) Choosing the appropriate assessment tool for the 
study population and its design is essential to maximise accuracy.(40) We modified the 
ESTEEM FFQ to use it as a user-friendly tool that would appeal to pregnant women who 
often had limited free time and low literacy. Overall the performance of our FFQ was similar 
to other validated FFQs for use in pregnant population on Mediterranean diet.(147,159,162) 
The low sensitivity and overestimation of certain food items suggest a limitation consistent 
with the use of self-reporting dietary assessment tools in general. Novel technological 
methods could improve the accuracy of self-reporting tools (163) such as mobile apps (164) 
and portable cameras (165), however, their applicability to pregnancy is still limited.   
 
Substituting the FFQ with a shorter and more focused questionnaire in dietary trials is 
common.(166) The performance of the ESTEEM Q supports its validity to assess the 
participants’ adherence to the Mediterranean-based dietary intervention. Linking the scores 
derived from The ESTEEM Q to pregnancy outcomes will help evaluate the effect of 
adherence on health outcomes.(152)  
 
6.6 Conclusion 
Our modified FFQ and ESTEEM Q are useful tools to assess adherence to a Mediterranean-







CHAPTER 7  
 
PRAGMATIC MULTICENTRE RANDOMISED 
TRIAL ON THE EFFECT OF SIMPLE, 
TARGETED DIET IN PREGNANT WOMEN 
WITH METABOLIC RISK FACTORS ON 






Introduction Mediterranean diet can help to reduce metabolic risk factors and improve 
pregnancy outcomes. We conducted a randomised trial (ESTEEM) to evaluate the 
effectiveness of a Mediterranean-based dietary intervention on maternal and fetal outcomes.  
Methods ESTEEM was an open-label randomised trial recruiting in five large maternity units 
for 24 months. We randomised pregnant women with metabolic risk factors to a 
Mediterranean-based dietary intervention or routine antenatal care using password protected 
internet-based computer system. We delivered the intervention over three sessions at 18, 20 
and 28 weeks gestation. We assessed adherence using a validated short dietary questionnaire. 
Our primary outcome was a composite maternal outcome (pre-eclampsia and/or gestational 
diabetes) and a fetal composite outcome (stillbirth, small for gestational age fetus and/or 
admission to the neonatal intensive care unit).  
Results In total, 1252 women were randomised. Both groups had similar basic characteristics 
with the majority of women being multigravidas, Asian and obese. The dietary intervention 
did not significantly reduce the primary maternal outcome (OR 0.99, 95% CI 0.72-1.36, 
p=0.95) or any of its composites (pre-eclampsia OR 1.48, 95% CI 0.87-2.50; GDM OR 0.86, 
95% CI 0.60-1.24). Gestational weight gain was significantly lower in the intervention group 
(OR -1.24, 95% CI -2.27-0.21, p=0.018). There was no significant effect on the composite 
fetal outcome (OR 0.79, 95% CI 0.58-1.07, p=0.13) or its composites (SGA OR 0.72, 95% CI 
0.51-1.04, p=0.07; stillbirth OR 0.49, 95% CI 0.04-5.57, p=0.56; admission to NICU OR 
0.79, 95% CI 0.53-1.19, p=0.26). Delivering the intervention resulted in a significant change 
of dietary intake towards a Mediterranean-based diet.  
Conclusions A Mediterranean-based dietary intervention is helpful to reduce gestational 
weight gain in pregnancy. The intervention did not improve maternal and fetal outcomes in a 
126 
 
high-risk population. Delivering a Mediterranean-based dietary intervention is feasible in a 







The worldwide epidemic of maternal obesity continues to grow rapidly especially in high-
income countries.(1,2) Almost every other women entering pregnancy in the UK and the 
USA is overweight or obese.(81) The adverse effect of obesity on pregnancy outcomes is 
well established.(5) Metabolic risk factors such as high BMI and dyslipidaemia significantly 
increase the risk of adverse maternal and fetal outcomes including pre-eclampsia (167), 
gestational diabetes (168), and fetal growth restriction.(169)  
 
Dietary and lifestyle interventions can help to reduce pre-existing metabolic risk factors and 
improve pregnancy outcomes.(8) Mediterranean based dietary interventions have a protective 
effect against cardiovascular and metabolic disease in the non-pregnant population.(48) 
Mediterranean diet, characteristic for high intake of vegetables, fish, olive oil and nuts, 
promotes greater intake of unsaturated fatty acids and helps to reduce oxidative stress from 
fatty tissues.(170) The effect of Mediterranean diet on reducing metabolic risk factors in 
pregnant women with has been reported in observational studies (50) but no randomised trials 
exist to date.   
 
We conducted a large multi-centre pragmatic randomised trial (ESTEEM) to evaluate the 
beneficial effect of a Mediterranean-based dietary intervention on composite maternal and 
fetal outcomes compared to routine antenatal care.    
 
7.3 Methods  
7.3.1 Study objectives 
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Our primary objective was to evaluate the effect of a simple, targeted Mediterranean-based 
diet, supplemented with extra-virgin olive oil and nuts, on a composite maternal and fetal 
outcome, compared to routine antenatal care within the National Health Service. Our 
secondary objectives were to assess the effect of the dietary intervention on various maternal 
and fetal clinical, dietary and biochemical outcomes.  
 
7.3.2 Study design  
I have discussed the study protocol and design in chapter 2. The protocol was registered and 
published prospectively.(146) The study was conducted as per the protocol with no recorded 
deviations.  
The primary outcome was a composite maternal outcome defined as pre-eclampsia (new 
onset or superimposed) or gestational diabetes; and a composite fetal outcome defined as 
stillbirth, small for gestational age fetus (birth weight less than 10th centile) or admission to 
the neonatal intensive care unit. (Appendix 7)  
 
The secondary outcomes were  
maternal: pre-eclampsia, gestational diabetes, gestational weight gain, admission to high 
dependency unit or intensive care unit, antepartum haemorrhage, mode of delivery, preterm 
delivery (<37 weeks, and < 34 weeks), anaemia, and physical activity.  
fetal and neonatal: small for gestational age (<10th centile), very small for gestational age (< 
3rd centile ), large for gestational age (> 90th centile), stillbirths, birth weight (in Kg using 
both customised and population centiles), admission to neonatal intensive care units, neonatal 
deaths, and hypoxic ischaemic encephalopathy.  
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dietary: food intake for olive oil, nuts, vegetables, fish, fruits, pulses, red meat, white meat, 
butter/margarine, sugary drinks, commercial sweets, and micronutrients.  
laboratory:  maternal serum lipids including levels of triglycerides, high-density lipoproteins 
(HDL), the ratio of triglycerides (ratio of triglycerides to HDL ) and non-high-density 




We screened 8328 pregnant women; 3421 met our inclusion criteria for ESTEEM 
(3421/8328, 41%). In total, 1252 women with metabolic risk factors and were randomised to 












Women assessed for eligibility (n= 8328) 
Excluded (n= 5163) 
 Not meeting inclusion criteria (n= 2656) 
 Declined to participate (n= 2519) 
 Other reasons (n= 22) 
Allocated to targeted ESTEEM diet (n= 627) 
 
Lost to follow-up (n= 27) 
 
Allocated to routine antenatal care (n= 625) 
 
Analysed (n= 585) 
 
 
Randomised (n= 1252) 
Recruited to ESTEEM (n= 3421) 
Allocated to cohort group (n= 2169) 
Recruited in error (n=9) 
Patient request (n=4) 
Invalid consent (n=0) 
 
Recruited in error (n=24) 
Patient request (n=7) 
Invalid consent (n=3) 
 
Lost to follow-up (n= 40) 
 





7.4.1 Population characteristics 
The baseline characteristics were similar in both groups. The average participant age was 31 
and about 3% were above the age of 40. Both groups had similar basic characteristics with 
the majority of women being multigravidas, Asian and obese (Table 7.4.1). Serum lipids, 
previous clinical and family history were all comparable between the groups. Overall, 41% of 
the participants in the intervention group were compliant and attended all the planned 
intervention sessions. A summary of baseline dietary intake, physical activity and quality of 
life assessment is provided in Appendix (8).  
Table (7.4.1): Baseline characteristics of participants in the ESTEEM trial.  
 
Baseline characteristics Intervention Control 
Demographics (584,610)   
Age (years)  





































Clinical history   
Pre-eclampsia / Eclampsia / HELLP 
(575,600) 
Gestational Diabetes (563,585) 
Stillbirth / Neonatal Death (571,598) 
Admission to ITU / HDU (530,557) 
Chronic hypertension (554,575) 
Family history of hypertension/pre-
eclampsia (537,536) 















Baseline serum lipids   
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Triglycerides (mmol/L) (532,558) 
HDL (mmol/L) (531,557) 
Ratio of Triglycerides to cholesterol 
(527,553) 









Health Thermometer (400,222) 67.4 (18.7) 71.8 (18.7) 
ESTEEM Q diet score (337,210) 5.0 (1.9) 5.0 (1.9) 
Physical Activity (MET) (406, 241) 2579.5 (3335.9) 2591.7 (3306.9) 
Data are mean (SD) or numbers (percentage)  
ITU: intensive treatment unit, HDU: high dependency unit, HDL: high density lipoprotein, LDL: low density lipoprotein. MET: Metabolic Equivalent of Task 
minutes per week.  
 
 7.4.2 Primary outcomes 
 The intention to treat analysis demonstrated some protective effect of the dietary intervention 
on reducing the primary maternal outcome (OR 0.76, 95% CI 0.56-1.03, p=0.07) with more 
visible effect against GDM (OR 0.65, 95% CI 0.47-0.91, p=0.01) than pre-eclampsia (OR 
1.43, 95% CI 0.84-2.43, p=0.19). This was further confirmed in our CACE analysis for 
primary maternal composite outcome (OR 0.55, 95% CI 0.29-1.05, p=0.06). In contrast, there 
was no major effect for the intervention to reduce the incidence of the composite fetal 
outcome (OR 0.79, 95% CI 0.58-1.08, p=0.14) or any of its composites (small for gestation 
age OR 0.78, 95% CI 0.53-1.15, p=0.21; stillbirth OR 0.49, 95% CI 0.04-5.57, p=0.56; 
admission to NICU OR 0.79, 95% CI 0.53-1.18, p=0.25). The protective effect of the 
intervention was more evident (OR 0.59, 95% CI 0.32-1.07, p=0.07) when accommodating 
for adherence with the intervention. (Table 7.4.2).  
 
Table (7.4.2): Effects of Mediterranean diet on the primary composite maternal and fetal and 
neonatal outcomes, and its components  

















Composite maternal outcome (486,500) 111 (22.8%) 143 (28.6%) 0.74 (0.55, 
0.98) 
0.03 0.76 (0.56, 1.03) 0.07 
Composite fetal outcome (550,583) 92 (17.3%) 118 (20.9%) 0.79 (0.59, 
1.07) 
0.13 0.79 (0.58, 1.08) 0.14 
Primary outcome (CACE Analyses)  
Composite maternal Outcome (Pre-








0.02 0.55 (0.29, 1.05) 0.06 
Composite fetal Outcome (stillbirth and/or 
admission to NICU and/or small for 
gestational age.  
 




0.11 0.59 (0.32, 1.07) 0.07 
Individual outcomes 
Gestational diabetes (477,497) 84 (17.6%)  124 (24.9%) 0.64 (0.47, 
0.88) 
0.00 0.65 (0.47, 0.91) 0.01 
Pre-eclampsia (552,585) 34 (6.2%)  27 (4.6%)  1.36 (0.81, 
2.28) 
0.25 1.43 (0.84, 2.43) 0.19 
Small for gestational age (550,583) 52 (9.8%)  69 (12.2%)  0.78 (0.53, 
1.14) 
0.20 0.78 (0.53, 1.15) 0.21 
Stillbirth (552,585) 1 (0.2%)  2 (0.4%)  0.53 (0.05, 
5.86) 
0.60 0.49 (0.04, 5.57) 0.56 
Admission to NICU (552, 584) 49 (9.2%)  64 (11.3%)  0.79 (0.54, 
1.17) 
0.25 0.79 (0.53, 1.18) 0.25 
GDM: gestational diabetes mellitus NICU: neonatal intensive care unit 
 
 
Subgroup analysis for obesity, raised Triglycerides and raised blood pressure at booking, did 
not demonstrate any major differences in the effect of the intervention on the primary 
outcome or its maternal and fetal composites  (Table 7.4.3).  
Table (7.4.3): The effect of the dietary intervention on primary outcomes across the different 
randomisation subgroups.   
 
   Included in Analysis Experienced Outcome Adjusted Odds 
Ratio (95% CI) 
P value 
Intervention Control Intervention Control 
Primary Maternal Outcome        
 Obese 
348 352 81 (23.3%) 
104 
(29.5%) 
0.72 (0.50, 1.02) 0.55 
 Not Obese   138 148 30 (21.7%) 39 (26.4%) 0.88 (0.50, 1.57)  
               
 Raised Triglycerides 199 212 50 (25.1%) 71 (33.5%) 0.68 (0.43, 1.08) 0.59 
 Not Raised 
Triglycerides   
243 245 51 (21.0%) 61 (24.9%) 0.81 (0.52, 1.26)   
         
 Raised Blood 
Pressure   
30 27 10 (33.3%) 14 (51.9%) 0.60 (0.19, 1.89) 0.67 
 Not Raised Blood 
Pressure   
448 461 100 (22.3%) 
125 
(27.1%) 
0.78 (0.57, 1.07)  
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Pre-eclampsia        
 Obese 386 409 26 (6.7%) 18 (4.4%) 1.65 (0.88, 3.11) 0.40 
 Not Obese   166 176 8 (4.8%) 9 (5.1%) 0.99 (0.37, 2.69)  
               
 Raised Triglycerides  230 252 11 (4.8%) 11 (4.4%) 1.13 (0.47, 2.71) 0.91 
 Not Raised 
Triglycerides   
270 280 18 (6.7%) 16 (5.7%) 1.21 (0.59, 2.46)   
         
 Raised Blood 
Pressure 




 Not Raised Blood 
Pressure   
507 542 27 (5.3%) 24 (4.4%) 1.26 (0.71, 2.24)  
Gestational Diabetes            
 Obese   341 349 61 (17.9%) 92 (26.4%) 0.58 (0.40, 0.86) 0.27 
 Not Obese   136 148 23 (16.9%) 32 (21.6%) 0.88 (0.47, 1.65)  
               
 Raised Triglycerides   195 212 41 (21.0%) 63 (29.7%) 0.64 (0.39, 1.04) 0.86 
 Not Raised 
Triglycerides   
238 242 36 (15.1%) 50 (20.7%) 0.68 (0.41, 1.11)   
         
 Raised Blood 
Pressure   
27 27 5 (18.5%) 13 (48.1%) 0.28 (0.07, 1.07) 0.19 
 Not Raised Blood 
Pressure   
442 458 78 (17.6%) 
107 
(23.4%) 
0.70 (0.50, 1.00)   
Primary Fetal Outcome       
 Obese   373 392 61 (16.4%) 86 (21.9%) 0.69 (0.48, 1.01) 0.20 
 Not Obese   158 172 31 (19.6%) 32 (18.6%) 1.08 (0.61, 1.89)  
               
 Raised Triglycerides  223 242 38 (17.0%) 45 (18.6%) 0.94 (0.58, 1.52) 0.37 
 
Not Raised 
Triglycerides   
258 270 46 (17.8%) 63 (23.3%) 0.69 (0.45, 1.07)   
         
 
Raised Blood 
Pressure   
35 28 16 (45.7%) 6 (21.4%) 3.08 (0.97, 9.77) 0.018 
 
Not Raised Blood 
Pressure   
487 523 76 (15.6%) 
108 
(20.7%) 
0.72 (0.52, 1.00)   
        
Small for Gestational Age(2) 
  
Obese(3) 375 397 33 (8.8%) 51 (12.8%) 0.65 (0.41, 1.03) 0.28 
Not Obese   160 174 19 (11.9%) 21 (12.1%) 1.02 (0.52, 2.00)  
               
Raised Triglycerides(4)   218 239 20 (9.2%) 23 (9.6%) 1.00 (0.53, 1.91) 0.22 
Not Raised Triglycerides   256 271 27 (10.5%) 42 (15.5%) 0.60 (0.35, 1.02)   
        
Raised Blood Pressure(5)   35 29 10 (28.6%) 5 (17.2%) 2.02 (0.58, 7.02) 0.093 
Not Raised Blood Pressure   491 529 42 (8.6%) 66 (12.5%) 0.66 (0.43, 0.99)  
       
Admission to Neonatal ICU       
Obese   386 409 36 (9.3%) 45 (11.0%) 0.86 (0.53, 1.38) 0.60 
Not Obese   166 175 13 (7.8%) 19 (10.9%) 0.67 (0.31, 1.45)  
              
Raised Triglycerides   230 251 20 (8.7%) 29 (11.6%) 0.74 (0.40, 1.37) 0.73 
Not Raised Triglycerides   270 280 26 (9.6%) 32 (11.4%) 0.86 (0.49, 1.52)   
       













7.4.3 Secondary outcomes 
Mothers in the intervention group had lower gestational weight gain compared to the control 
group (OR -1.18, 95% CI -2.27-0.15, p=0.02). All other secondary maternal outcomes were 
similar in both groups (Table 3). Using population charts, the incidence of small of 
gestational age was reduced in the intervention group (OR 0.73, 95% CI 0.51-1.04, p=0.08), 
this however was not the case when GROW charts were used (OR 0.78, 95% CI 0.53-1.15, 
p=0.21). None of the other secondary fetal outcomes were different between the two groups 





Table (7.4.4): Secondary maternal and fetal outcomes in the ESTEEM trial on the effect of a 
Mediterranean-based dietary intervention in pregnant women with metabolic risk factors.  
 














Gestational Weight Gain (Kg) 
(230,238) 







Preterm Delivery <37 Weeks 
(545,579) 
52 (9.5%)  64 (11.1%)  0.85 (0.58, 1.25) 0.41 0.82 (0.55, 1.22) 0.33 
Preterm Delivery <34 
Weeks(545,579) 
23 (4.2%)  26 (4.5%)  0.94 (0.53, 1.66) 0.82 0.92 (0.51, 1.67) 0.79 
Antepartum Haemorrhage(548,580) 9 (1.6%)  13 (2.2%)  0.73 (0.31, 1.72) 0.47 0.70 (0.29, 1.72) 0.44 
Mode of Delivery       
Vaginal delivery vs. Caesarean 
Section 
Emergency Vs Elective Caesarean 
Section 











1.08 (0.84, 1.39) 
1.07 (0.69, 1.65) 
 





1.06 (0.82, 1.37) 
1.28 (0.77, 2.12) 
 





Anaemia (547,578) 114 (20.8%)  129 (22.3%)  0.92 (0.69, 1.22) 0.55 0.91 (0.66, 1.23) 0.53 
Admission to HDU or ITU (527,566) 18 (3.4%)  24 (4.2%)  0.80 (0.43, 1.49) 0.48 0.79 (0.42, 1.50) 0.48 
Fetal outcomes 
Hypoxic ischaemic encelopathy 
(550,580) 
2 (0.4%)  4 (0.7%)  0.53 (0.10, 2.89) 0.46 0.56 (0.09, 3.46) 0.53 
Neonatal Death (551,585) 







Birth Weight (g) (550.584) 







Small for Gestational Age 
(GROW)(550,584) 
52 (9.8%)  69 (12.2%)  0.78 (0.53, 1.14) 0.20 0.78 (0.53, 1.15) 0.21 
Small for Gestational Age 
(Population) (550,583) 
61 (11.5%)  86 (15.2%)  0.72 (0.51, 1.03) 0.06 0.73 (0.51, 1.04) 0.08 
Very small for Gestational Age 
(GROW)(550,583) 
17 (3.2%)  21 (3.7%)  0.86 (0.45, 1.64) 0.64 0.84 (0.43, 1.63) 0.60 
Very small for Gestational Age 
(Population) (550,583) 
30 (5.6%)  33 (5.9%)  0.96 (0.58, 1.60) 0.89 0.96 (0.57, 1.61) 0.87 
Large for Gestational Age (GROW) 
(550,583) 
73 (13.7%)  64 (11.3%)  1.25 (0.87, 1.78) 0.23 1.23 (0.86, 1.78) 0.26 
Large for Gestational Age 
(Population) (550,583) 
59 (11.1%)  61 (10.8%)  1.03 (0.71, 1.51) 0.88 1.01 (0.69, 1.49) 0.94 
Laboratory outcomes  
Triglycerides (mmol/L)(217,257) 







HDL (mmol/L) (221,258) 







Ratio of Triglycerides (215,255) 







Non-HDL (mmol/L) (219,256) 







Physical and dietary outcomes 
Physical Activity (MET) (262,270) 







ESTEEM Q diet score (218,255) 7.2 (2.0) 5.1 (2.0) 2.06 (1.70, 2.43) 0.00 2.00 (1.66, 2.33) 0.00 




7.4.4 Dietary intake  
Participants in the intervention group consumed more key foods in the Mediterranean diet 
including extra virgin olive oil (p=<0.001), nuts (p=<0.001), pulses (p=0.047), fish 
(p=<0.001), and white meat (p=<0.001). They also consumed less red meat (p=<0.001), and 
butter margarine (p=<0.001). Both groups reported similar GI symptoms with less 
bloatedness in the intervention group (p=0.03) (Table 7.4.5). 
 
Table (7.4.5): Summary of participants’ dietary intake at 36 weeks gestation  














Do you use olive oil as the main 
fat to cook with? (Yes) 
 
261 (93.2%) [273] 146 (49.0%) [287] 14.30 (8.52, 
24.01) 
<0.001 32.19 (16.03, 
64.62) 
<0.001 
How many tablespoons do you 
consume of olive oil in a given 
day? (>=4) 
 
63 (23.1%) [280] 28 (9.5%) [289] 2.87 (1.78, 4.64) <0.001 2.81 (1.55, 5.09) <0.001 
How many servings of 
vegetable do you consume per 
day? (>=2) 
 
185 (67.5%) [279] 189 (64.5%) [292] 1.14 (0.81, 1.62) 0.45 1.34 (0.85, 2.11) 0.21 
How many fruit units do you 
consume per day? (>=3) 
 
142 (51.4%) [277] 156 (52.7%) [289] 0.95 (0.68, 1.32) 0.76 1.10 (0.72, 1.68) 0.66 
How many servings of red meat, 
processed meat or red meat 
products do you consume per 
day (<1) 
 
206 (85.5%) [312] 156 (56.1%) [307] 4.60 (3.00, 7.07) <0.001 3.42 (1.99, 5.86) <0.001 
How many servings of butter, 
margarine, or cream do you 
consume per day? (<1) 
 
164 (61.2%) [285] 115 (39.5%) [294] 2.41 (1.72, 3.39) <0.001 2.41 (1.55, 3.75) <0.001 
How many drinks containing 
sugar do you consume per day? 
(<1) 
 
149 (55.4%) [284] 121 (41.0%) [290] 1.79 (1.28, 2.49) <0.001 1.40 (0.92, 2.15) 0.12 
How many servings of pulses do 
you consume per week? (>=3) 
 
103 (37.5%) [278] 86 (29.1%) [289] 1.46 (1.03, 2.08) 0.033 1.56 (1.00, 2.44) 0.048 
How many servings of fish or 
shellfish do you consume per 
week? (>=3) 
 
101 (36.6%) [277] 67 (22.6%) [288] 1.98 (1.37, 2.86) <0.001 2.57 (1.57, 4.21) <0.001 
How many times per week do 
you consume commercial 
sweets or pastries, such as 
165 (59.8%) [277] 151 (51.7%) [293] 1.39 (1.00, 1.94) 0.053 1.42 (0.92, 2.19) 0.11 
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cakes, cookies, biscuits or 
custard? (<3) 
 
How many servings of nuts do 
you consume per week? (>=3) 
 
192 (70.1%) [279] 67 (22.9%) [293] 7.86 (5.40, 
11.45) 
<0.001 6.75 (4.28, 
10.62) 
<0.001 
Do you preferentially consume 
chicken or turkey instead of 
veal, pork, hamburger or 
sausage? (Yes) 
 
221 (87.0%) [299] 224 (80.3%) [306] 1.64 (1.03, 2.63) 0.038 2.34 (1.26, 4.35) 0.007 
Mean total Score 7.2 (2.0) [335] 5.1 (2.0) [330] 2.06 (1.70, 2.43) <0.001 2.00 (1.66, 2.33) <0.001 
Symptoms Experienced 
Fullness of stomach 151 (56.8%) [287] 157 (62.5%) [334] 0.79 (0.55, 1.12) 0.18 0.93 (0.60, 1.43) 0.73 
Bloatedness 76 (28.5%) [286] 92 (36.8%) [335] 0.68 (0.47, 0.99) 0.044 0.61 (0.39, 0.96) 0.032 
Vomiting 35 (13.2%) [287] 44 (17.6%) [335] 0.71 (0.44, 1.15) 0.16 0.61 (0.33, 1.14) 0.12 
Nausea 70 (26.2%) [286] 83 (32.9%) [333] 0.72 (0.50, 1.06) 0.09 0.82 (0.52, 1.31) 0.41 
Indigestion 126 (47.2%) [286] 110 (44.0%) [335] 1.14 (0.80, 1.61) 0.47 1.08 (0.69, 1.69) 0.73 
Constipation 70 (26.2%) [286] 82 (32.7%) [334] 0.73 (0.50, 1.07) 0.11 0.73 (0.46, 1.15) 0.17 
Diarrhoea 32 (12.1%) [288] 39 (15.6%) [335] 0.74 (0.45, 1.23) 0.25 0.60 (0.34, 1.09) 0.093 







The EQ-5D questionnaire revealed similar quality of life status for both groups with an 
overall health mean difference score of 2.98 (p=0.04) (Table 7.4.6).  
 
Table (7.4.6): Summary of the participants’ quality of life using the EQ-5D questionnaire at 
36 weeks gestation.  
Quality of life dimension Intervention (n=553) Control  
(n=585) 
Odds Ratio (95% CI) P Value 
Mobility 83 (29.6%) [273] 84 (28.1%) [286] 1.06 (0.68, 1.64) 0.80 
Self-Care 25 (9.0%) [274] 36 (12.0%) [286] 0.73 (0.37, 1.46) 0.37 
Usual Activities 88 (31.7%) [275] 102 (34.0%) [285] 0.88 (0.57, 1.35) 0.55 
Pain/Discomfort 174 (62.4%) [274] 189 (63.2%) [286] 0.91 (0.60, 1.38) 0.65 
Anxiety/Depression 53 (19.1%) [275] 59 (19.7%) [286] 1.07 (0.65, 1.78) 0.78 
Health Thermometer 73.1 (16.9) [296] 69.9 (18.6) [333] 2.98 (0.05, 5.91) 0.04 




7.5.1 Summary of findings 
Our findings demonstrate the overall beneficial effect of a Mediterranean-based diet in 
improving pregnancy outcomes in a high risk population particularly in reducing the incidence 
of gestational diabetes and gestational weight gain. This effect was more pronounced in those 
mothers who complied fully with the intervention and lead a gestational weight gain reduction 
by an average of 1.24 Kg. The effect on fetal outcome was less evident particularly when using 
GROW charts compared to standardised population charts. The uptake for the Mediterranean 
diet in our multi-ethnic population. Compared to baseline, the intervention group significantly 
consumed more for key food items such as fish, olive oil, nuts and chicken with less intake of 
meat and butter. Women approached to join the study were generally in favour of taking up the 
intervention with only 30% declining to participate (2519/8328, 30%). This was significantly 
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higher compared to similar studies evaluating lifestyle interventions in pregnancy with a 
decline to participate rate between 50-60%.(54,132,172) Delivering the intervention in the 
antenatal period, therefore, seems feasible.   
 
7.5.2 Strengths and limitations 
We used a prospective protocol that was registered and published prospectively. The large 
sample size provided enough power to detect a reduction in the primary outcome. This was 
supported by the small number of loss to follow-up cases. Our inclusion and randomisation 
criteria were relaxed, increasing the external validity of the findings. The generalisability of 
ESTEEM is high due to its pragmatic design and the large mix of ethnicities and 
socioeconomic backgrounds in our population. We performed an intention to treat analysis 
and supplemented it with a CACE analysis to accommodate for the participants’ adherence to 
the intervention. We used minimisation to eliminate potential effect modifiers. We assessed 
the participants’ physical activity and quality of life, two important elements for evaluating 
complex behavioural interventions. We adapted the intervention to local food culture by 
providing cooking recipes and used validated assessment tools to assess dietary intake.  
 
Blinding the participants in nutritional studies is complex.(79) The lack of blinding in 
ESTEEM leaves a chance for the Hawthorne effect.(171) We did not introduce a control diet 
in the comparison group and some of the participants’ might have followed a Mediterranean 
diet. We focused on increasing the intake of unsaturated fatty acids to reduce oxidative stress 
in pregnancy. However, due to limitations in the dietary assessment methods, we could not 
objectively compare the intake of these nutrients between the two groups. Furthermore, 
serum lipids assessment was only possible when performed randomly. Measuring fasting 
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serum values could arguably offer a more accurate view on the effect on lipids, however, this 
was not logistically possible within our trial settings. Our population was mainly obese and 
multigravida. The risk of pre-eclampsia and gestational diabetes might be different in lean 
nulliparous women. The adherence to the interception was suboptimal (41%), however, this 
is comparable to other dietary trials in pregnancy.(54,172) 
 
7.5.3 Implications for future practice 
Dietary and behavioural interventions in pregnancy were shown to improve maternal and 
fetal outcomes in a number of small trials, however, most suffer from methodological 
limitations.(8) Our findings, come in line with the results of recently published large trials 
suggesting some protective effect of dietary interventions on pregnancy 
outcomes.(54,132,172) However, our trial demonstrates a clear protective effect against 
gestational diabetes in contrast to these large trials.(54,132,172) This could be attributed to 
many factors.; the specific nature of Mediterranean diet might make it easier to follow by 
pregnant women leading to higher adherence and greater effect. Engaging mothers to be 
active in delivering the intervention could also have helped to improve adherence. Lastly, the 
criteria used to diagnose gestational diabetes varies as we used the the modified International 
Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria.(173)  
In particular, ESTEEM supports the role of diet in reducing gestational weight gain, which is 
well established in available evidence.(8) Increased weight gain in pregnancy can act as a 
surrogate for adverse maternal and fetal outcomes such as gestational diabetes and small for 
gestation age.(174) However, establishing a linear link between diet, weight gain and 




The planned intervention sessions in ESTEEM were quite moderate in frequency and 
intensity. Delivering a more concentrated intervention might yield better health outcomes, 
however and quite possibly, it won’t be feasible in modern health systems such as the NHS 
nor cost-effective.(175) Several studies have demonstrated a protective effect for 
Mediterranean diet on childhood obesity, asthma, and allergy.(176,177) The planned follow-
up for ESTEEM mothers and babies will help to assess the long-term health outcomes and 
the feasibility of enrolling such intervention after pregnancy. The uptake for Mediterranean 
diet in a multi-ethnic British population was quite high leading to a significant change in the 
dietary habits of the intervention group. With its proven long-term health benefits, sustaining 
the adherence to Mediterranean diet can help to reduce maternal and childhood obesity.(30)  
 
Much research evaluated the effect of dietary interventions on pregnancy outcomes with 
paradoxical findings.(83) This could be attributed to the methodological limitations and the 
large variations in the evaluated dietary regimes. Considering the findings of the ESTEEM 
trial, future studies should shift the focus to evaluating lifestyle interventions in different life 
periods such as pre-conception and postpartum. While ideal, delivering lifestyle interventions 
in the pre-conception period to optimise the pregnancy experience is not always feasible with 
more than 40% unplanned pregnancies in the UK.(173)  
 
7.6 Conclusion 
A Mediterranean-based dietary intervention in pregnant women with metabolic risk factors 
reduce the incidence of gestational diabetes and gestational weight gain. The implementation 
of Mediterranean diet in a multi-ethnic pregnant population is feasible and can improve 
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8.1 Summary of findings 
Table (8.1) presents a summary of the findings of my work relevant to the highlighted 
objectives of each chapter.  
 
Table (8.1): Summary of research findings for each chapter  
Chap
ter  
Population Intervention / test Outcome Study 
design 
Summary of results  
 How to evaluate the effect of Mediterranean-based dietary intervention on maternal and fetal outcomes in high-risk 

















The ESTEEM study was conducted as per the 
published protocol. We randomised 1252 
women to the trial and recruited 2169 women to 
the cohort study. The follow-up and future work 
on collected umbilical cord samples will help to 
evaluate the long-term effect of the dietary 
intervention on maternal and childhood 
outcomes.   

















I identified five key challenges encountered in 
ESTEEM: recruitment, intervention delivery, 
clinical staff engagement, adherence 
assessment, and defining outcomes. The 
solutions applied to ESTEEM will help to guide 
future research on dietary interventions in 
pregnancy.  
 What is the quality of online information on the risks and management of obesity in pregnancy? 

















I reviewed 53 websites and assessed their 
information and technological quality. There 
were 12 commercial, 18 governmental and 23 
NGO funded websites. The mean composite 
quality scores were not different among any of 
the websites groups. NGO funded websites that 
are obesity-specific and targeting healthcare 
users demonstrated higher overall quality 
scores. 
















Only two-thirds of available dietary trials in 
pregnancy assessed dietary intake using a 
specific tool. The most commonly used 
assessment tool was a multiple days’ food diary 
followed by a food frequency questionnaire. 
The majority of used tools were adopted and not 
validated within the study population. The use 
of a pre-defined adherence criteria was not 
common. There was no association between the 
choice of dietary assessment tools and study 
quality, study sample size, year of publication, 






8.2 Strengths and limitations 
The ESTEEM study was designed to provide an answer to an established gap in the literature 
on lifestyle interventions in pregnancy. The large sample size and pragmatic design provide 
high validity and generalisability to clinical practice. The tools used to evaluate dietary intake 
in the ESTEEM trial were validated and tailor-designed to increase accuracy within the study 
multi-ethnic population.  
I conducted the systematic reviews following a well-established methodology, used a 
prospective protocol, and reported the findings as per the PRISMA. I have developed the 
online information assessment to include technology assessment following recent 
recommendations.(178)  
The work presented suffers from certain limitations. The control group in the ESTEEM trial 
did not follow a neutral diet and some participants might already be following a 
Mediterranean lifestyle. The systematic review of online information included websites in 
 What is the validity of a food frequency questionnaire and a short questionnaire to assess the dietary intake of pregnant 











dietary intake in a 









The food frequency questionnaire and ESTEEM 
Q are useful tools for assessing the intake of key 
food items in the Mediterranean diet compared 
to 24 hour recalls. The FFQ overestimated the 
intake of energy and key micronutrients such as 
unsaturated fatty acids. The short ESTEEM 
questionnaire offered a suitable substitution for 
the long questionnaire when assessing 
participants’ adherence to the Mediterranean 
diet. Common gastro-intestinal disorders in 
pregnancy potentially increased the inter-rater 
variability for assessing dietary intake.  
 What is the effect of a Mediterranean-based dietary intervention on maternal and fetal outcomes in a pregnant population 
















A Mediterranean-based dietary intervention in 
pregnant women with metabolic risk factors 
reduces the incidence of gestational diabetes 
and gestational weight gain. The 
implementation of Mediterranean diet in a 
multi-ethnic pregnant population is feasible and 




English language only. Other developed countries like France and Holland could have some 
reliable internet-based information sources. The work on dietary validation did not adjust for 
energy intake and included a high-risk sample only. The intention to screen for validation 
methods used in pregnancy was limited by the small number of available studies.    
 
8.3 Implications for clinical practice 
- Introducing a Mediterranean-based diet during the antenatal period is feasible in a 
multi-ethnic British population. The intervention reduced the incidence of gestational 
diabetes, gestational weight gain and had some protective effect on reducing small for 
gestational age. Clinician should counsel pregnant women on the benefits of dietary 
interventions in pregnancy. Providing dietary advice following a well-established 
health lifestyle is more consistent than current recommendation by NICE.(57)  
 
- Delivering a Mediterranean-based dietary intervention in the second trimester of 
pregnancy might be insufficient to significantly improve maternal and fetal outcomes 
in a population with metabolic risk factors. Women at high risk of adverse outcomes 
should be counselled before conception on the benefits of lifestyle intervention and 
other preventive measures.  
 
 
- Obesity-specific websites targeting healthcare users and funded by non-governmental 
bodies offer good quality information on obesity in pregnancy. Clinicians and 





8.4 Implications for research 
- The effect of dietary interventions on long-term maternal and fetal outcomes is not 
well investigated. In particular, the effect of Mediterranean diet on childhood asthma 
and allergy is equivocal. The ESTEEM cohort will provide a medium for future 
follow-up studies to provide more insights on such effect. 
 
- The effect of dietary interventions on pregnancy outcomes is varied among existing 
studies due to differences in the choice of population, the intervention delivery, and 
the adherence. The ESTEEM findings will feed into a HTA funded individual patient 
data meta-analysis (IWIP) to enable high-quality evidence synthesis.  
 
 
- Evidence on the best tools to assess dietary intake in pregnancy is limited. 
Comparative studies are needed to assess the accuracy, sensitivity, and applicability 
of the various dietary tools to a pregnant population.  
 
- The use of novel technological and biochemical methods to assess dietary intake in 
pregnancy is limited. More studies are needed to investigate the role of such methods 
in pregnancy settings.   
 
 
- Substituting long food frequency questionnaires with short, more focused 
questionnaire is feasible to assess the adherence to dietary intervention in a pregnant 







Appendix (1): Contribution to each chapter 
- Chapter (1): I wrote the whole chapter solely 
- Chapter (2): I worked on drafting, updating and publishing the protocol for the 
ESTEEM study. I drafted the case report forms, dietary assessment questionnaires, 
and patient information sheet.  
- Chapter (3): I conceived the idea, conducted the analysis and wrote the first 
manuscript to publish the work related to this chapter 
- Chapter (4): I wrote the protocol for the systematic review, updated the search, 
analysed data and wrote the first manuscript.  
- Chapter (5): I wrote the protocol and the statistical analysis plan, I helped to collect 
primary data, I entered and processed the data, and wrote the first manuscript.  
- Chapter (6): I helped to manage the ESTEEM trial across 5 sites, I wrote site 
operational protocols, I recruited and randomised participants, I delivered the 
intervention at some centres, I collected outcomes and follow ups, I wrote the first 
draft of the manuscript.  
- Chapter (7): I wrote the protocol for the systematic review, conducted the primary 
search, analysed data and wrote the first manuscript. 
- ESTEEM study documents: I developed and revised the study case record file and the 
dietary assessment tools. The study information sheets, intervention documents, 
posters and consent forms were developed jointly with the study team 6 months 











Appendix (3): Participant consent forms for the ESTEEM study 








Appendix (4): Case report forms for the ESTEEM study 
A: Baseline CRF 
  













Appendix (5): ESTEEM Q, EQ5D, IPAQ, FFQ, and 24 hour recall questionnaires for the ESTEEM study 
A: ESTEEM Q 
 
B: EQ-5D 























Appendix (6): Intervention factsheets for the ESTEEM trial  





B: Individual portion weekly plan 
 
  
C: Extra virgin olive oil 
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D: Mixed nuts 







Appendix (7): Definition of the ESTEEM trial study outcomes.  
 
New Onset pre-eclampsia: 
New onset hypertension after 20 weeks gestation defined as systolic BP ≥ 140 mm Hg or 
diastolic BP ≥ 90 mmHg, in at least two readings, taken 4-6 hours apart plus new onset 
proteinuria defined as spot urine PCR test greater than 30mg/mmol or >24 hour urine 
300mg/24 hours or 2+ or more on standard urinary dipstick tests after 20 weeks gestation 
 
Superimposed pre-eclampsia in women with chronic hypertension or chronic proteinuria: 
In women with chronic hypertension and no proteinuria at baseline, the appearance of new 
onset proteinuria, (defined above) constitute a ‘superimposed pre-eclampsia’.  
 
Chronic hypertension is hypertension that is present at the booking visit or before 20 weeks 
or if the woman is already taking antihypertensive medication when referred to maternity. 
 
In women who had proteinuria at base line, the diagnosis of superimposed preeclampsia 
requires an elevated serum alanine aminotransferase concentration (>70 U per litre) or 
worsening hypertension (either two diastolic BP of at least 110 mm Hg four hours apart or 





Women with eclamptic seizures with no hypertension or proteinuria are considered to have 
pre-eclampsia. 
 
Gestational diabetes  
Defined as per the modified International Association of Diabetes and Pregnancy Study 
Groups (IADPSG) criteria—ie, fasting venous glucose of 5·1 mmol/L or higher or 2 h venous 
glucose of 8·5 mmol/L or higher, or a combination of these. 
 
Small for gestational age fetus  
Defined as birth weight less than 10th centile using gestation related optimal weight  
customised charts (GROW). 
Outcomes were collected as stated in the clinical notes by the supervising physician. We 
screened laboratory results to detect any abnormal biochemical results and link them to 
clinical notes. MEWS and drug charts were also screened to capture cases of pre-eclampsia in 
case a formal diagnosis has not been made in the clinical notes. Any ambiguity in capturing 




Appendix (8): Baseline dietary and quality of life measurements for participants in the 
ESTEEM trial 
 
A: ESTEEM Q  




Do you use olive oil as the main fat to cook with? (Yes) 154 (36.7%) [173] 110 (42.3%) [352] 
How many tablespoons do you consume of olive oil in a given day? (>=4) 45 (10.9%) [180] 28 (10.9%) [354] 
How many servings of vegetable do you consume per day? (>=2) 195 (46.7%) [175] 150 (58.8%) [357] 
How many fruit units do you consume per day? (>=3) 174 (41.3%) [172] 155 (59.4%) [351] 
How many servings of red meat, processed meat or red meat products do you consume 
per day (<1) 
293 (76.7%) [211] 123 (51.0%) [371] 
How many servings of butter, margarine, or cream do you consume per day? (<1) 224 (54.1%) [179] 105 (40.2%) [351] 
How many drinks containing sugar do you consume per day? (<1) 179 (42.6%) [173] 104 (40.3%) [354] 
How many servings of pulses do you consume per week? (>=3) 104 (24.9%) [175] 64 (24.7%) [353] 
How many servings of fish or shellfish do you consume per week? (>=3) 86 (20.6%) [175] 56 (21.5%) [352] 
How many times per week do you consume commercial sweets or pastries, such as 
cakes, cookies, biscuits or custard? (<3) 
225 (54.3%) [179] 146 (57.5%) [358] 
How many servings of nuts do you consume per week? (>=3) 101 (24.3%) [178] 54 (20.8%) [353] 
Do you preferentially consume chicken or turkey instead of veal, pork, hamburger or 
sausage? (Yes) 
276 (73.0%) [215] 185 (79.7%) [380] 
Mean total Score 5.0 (1.9) [256] 5.0 (1.9) [402] 
Symptoms Experienced     
Fullness of stomach 255 (63.0%) [188] 147 (66.5%) [391] 
Bloatedness 223 (54.9%) [187] 128 (58.7%) [394] 
Vomiting 139 (34.2%) [187] 60 (26.9%) [389] 
Nausea 209 (51.6%) [188] 127 (56.4%) [387] 
Indigestion 182 (44.8%) [187] 95 (44.0%) [396] 
Constipation 165 (40.7%) [188] 95 (44.2%) [397] 






Quality of life dimension Intervention (n=551) Control (n=586) 
Mobility   
I have no problems in walking about 356 (86.0%) 220 (85.3%) 
I have some problems in walking about 57 (13.8%) 37 (14.3%) 
I am confined to bed 1 (0.2%) 1 (0.4%) 
Missing data 179 354 
Self-Care     
I have no problems with self-care 397 (95.9%) 252 (97.3%) 
I have some problems with washing or dressing myself 15 (3.6%) 7 (2.7%) 
I am unable to wash or dress myself 2 (0.5%) 0 (0.0%) 
Missing data 179 353 
Usual Activities     
I have no problems with performing my usual activities 348 (84.1%) 200 (77.8%) 
I have some problems with performing my usual activities 63 (15.2%) 54 (21.0%) 
I am unable to perform my usual activities 3 (0.7%) 3 (1.2%) 
Missing data 179 355 
Pain/Discomfort     
I have no pain or discomfort 221 (53.6%) 139 (53.5%) 
I have moderate pain or discomfort 177 (43.0%) 116 (44.6%) 
I have extreme pain or discomfort 14 (3.4%) 5 (1.9%) 
Missing data 181 352 
Anxiety/Depression     
I am not anxious or depressed 329 (79.5%) 213 (81.9%) 
I am moderately anxious or depressed 80 (19.3%) 44 (16.9%) 
I am extremely anxious or depressed 5 (1.2%) 3 (1.2%) 
Missing data 179 352 




Appendix (9): Search Strategy for randomised trials using dietary assessment tools in 
pregnancy 
Ovid MEDLINE(R) 1950 to Present with Daily Update 
# Searches Results 
1 Obesity/ 88629 
2 *obesity/ 60169 
3 *Obesity/ 60169 
4 
obes*.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier] 
136045 
5 1 or 2 88629 
6 1 or 4 136045 
7 3 or 4 136045 
8 1 or 2 or 3 or 4 136045 
9 Overweight/ 4443 
10 exp Overweight/ 97104 
11 *Overweight/ 2653 
12 
overweight.mp. [mp=title, original title, abstract, name of substance word, subject heading word, 
unique identifier] 
21031 
13 9 or 10 97104 
14 10 or 11 97104 
15 11 or 12 21031 
16 exp Obesity/ 97173 
17 1 or 16 97173 
18 4 or 16 137405 
19 




(body adj weight).mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier] 
219574 
21 
(body adj2 weight).mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier] 
221994 
22 
(body and weight).mp. [mp=title, original title, abstract, name of substance word, subject heading 





(body or weight).mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier] 
1116567 
24 20 or 21 221994 
25 21 or 22 258855 
26 21 or 23 1116567 
27 22 or 23 1116567 
28 9 or 10 or 11 or 12 103377 
29 10 or 12 103377 
30 1 or 2 or 3 or 4 or 16 137405 
31 20 or 21 or 22 or 23 1116567 
32 *body weight/ 18917 
33 
body weight*.mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier] 
223873 
34 31 or 32 1116567 
35 31 or 33 1116567 
36 
weight change.mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier] 
2930 
37 
(weight adj2 change).mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier] 
3831 
38 
weight change*.mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier] 
4937 
39 
weight chang*.mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier] 
4943 
40 
(weight adj2 chang*).mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier] 
7250 
41 36 or 37 3831 
42 36 or 38 4937 
43 36 or 39 4943 
44 36 or 40 7250 
45 37 or 38 5816 
46 37 or 39 5822 
47 37 or 40 7250 
48 38 or 39 4943 
169 
 
49 39 or 40 7250 
50 38 or 40 7250 
51 36 or 37 or 38 or 39 or 40 7250 
52 




(weight adj2 lose).mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier] 
1772 
54 




(weight adj2 lose*).mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier] 
1841 
56 




(weight adj2 los*).mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier] 
46316 
58 52 or 53 1772 
59 52 or 54 78 
60 52 or 55 1841 
61 52 or 56 42923 
62 52 or 57 46316 
63 53 or 54 1821 
64 53 or 55 1841 
65 53 or 56 43645 
66 53 or 57 46316 
67 54 or 55 1841 
68 54 or 56 42923 
69 54 or 57 46316 
70 55 or 56 43659 
71 55 or 57 46316 
72 56 or 57 46316 
73 52 or 53 or 54 or 55 or 56 or 57 46316 
74 
excessive weight gain.mp. [mp=title, original title, abstract, name of substance word, subject 





excessive weight gain*.mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier] 
473 
76 
(excessive adj2 weight adj2 gain).mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
571 
77 
(excessive adj2 weight adj2 gain*).mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
599 
78 74 or 75 473 
79 74 or 76 571 
80 74 or 77 599 
81 75 or 76 581 
82 75 or 77 599 
83 76 or 77 599 
84 74 or 75 or 76 or 77 599 
85 28 and 30 and 31 and 51 and 73 and 84 3 
86 28 or 30 or 31 or 73 or 84 1187097 
87 from 86 keep 1-100 100 
 







Appendix (10): Bland – Altman plots of estimated food and nutrients mean values from the 
































































































































































































































































































































































































































































































































Energy (kcal) Energy-adjusted Protein  
  
Energy-adjusted carbohydrates  Protein (g) 
  
Carbohydrates (g) Sugar (g) 
  
Non-starch polysaccharides (g) Energy-adjusted saturated Fatty Acids  
  













































































































































































































































































































Energy-adjusted mono-unsaturated Fatty Acids  Linoleic Acid (mg) 
  
Marine n3 Fatty Acids (g) Sodium (mg) 
  
Calcium (mg) Cholesterol (mg) 
  








































































































































































































































































































Phosphorus (mg) Copper (mg) 
  
Chloride (mg) Iron (mg) 
  
Zinc (mg) Manganese (mg) 
  

























































































































































































































































































































Vitamin D (µg) Selenium (µg) 
  
Carotene (µg) Vitamin E (µg) 
  
Thiamine (mg) Niacin (mg) 
  












































































































































































































































































































Vitamin B6 (mg) Folate (µg) 
  
Pantothenate (mg) Vitamin C (mg) 
  

















































































































































































































































































Appendix (11): Search Strategy used for online websites providing information on obesity in 
pregnancy. 
 
[obese] OR [obesity] AND [pregnan*] 
[overweight] AND [pregnan*]  
[high BMI] AND [pregnan*]  
[plus size] AND [pregnan*] 
[healthy lifestyle] AND [pregnan*] 
[diet] AND [pregnan*] 
[obese] OR [obesity] AND [mother] OR [maternal] 
[overweight] AND [mother] OR [maternal] 
[high BMI] AND [mother] OR [maternal] 
[plus size] AND [mother] OR [maternal] 
[healthy lifestyle] AND [mother] OR [maternal] 





Appendix (12): The PRISMA checklist for reporting systematic reviews 
Section/topic  # Checklist item  
TITLE  
Title  1 Identify the report as a systematic review, meta-analysis, or both.  
ABSTRACT  
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
INTRODUCTION  
Rationale  3 Describe the rationale for the review in the context of what is already known.  
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 




5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it 
could be repeated.  
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, 
if applicable, included in the meta-analysis).  
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from investigators.  
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis.  
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures 
of consistency (e.g., I2) for each meta-analysis.  
 











Section/topic  # Checklist item  
180 
 
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
RESULTS  
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons 
for exclusions at each stage, ideally with a flow diagram.  
Study 
characteristics  
18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-
up period) and provide the citations.  
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 
12).  
Results of 
individual studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression 




24 Summarize the main findings including the strength of evidence for each main outcome; consider 
their relevance to key groups (e.g., healthcare providers, users, and policy makers).  
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias).  
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for 
future research.  
FUNDING  
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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analysis. Evidence-based Medicine. 2016 Dec 1. 
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gynaecology (UKARCOG). B.H.Al Wattar. Management of obstetric post-partum 
haemorrhage: A UK national audit of practice. Risk Management and Healthcare 
Policy. In press.  
 
 
- Al Wattar, B.H., 2016. Weave your own web. BJOG: An International Journal of 
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